  
 
1  
Study Title:   
Genomic Medicine for Ill Neonates and Infants  
(The GEMINI Study)  
Grant Title:  Precision Medicine in the Diagnosis of Genetic 
Disorders in Neonates (U01TR002271)  
NCT Identified 
Number:  [STUDY_ID_REMOVED]  
Co-Principal 
Investigators:    
 Jonathan M. Davis, MD  
The Floating Hospital for Children at Tufts Medical 
Center  
Tel: 617 -636-5322  
E-mail: jdavis@tuftsmedicalcenter.org  
 
Jill Maron, MD, MPH  
The Floating Hospital for Children at Tufts Medical 
Center  
Tel: 617 -636-0766  
E-mail: jmaron@tuftsmedicalcenter.org  
Pager: 617 -647-2971  
 
Project 
Manager:  Anne Kurfiss, MPH  
The Floating Hospital for Children at Tufts Medical 
Center  
Tel: 617-636-7134  
E-mail: akurfiss@tuftsmedicalcenter.org  
Funded by:  National Center for Advancing Translational Sciences 
(NCATS)  
Protocol 
Version:  2.0, 05DEC 2019  
  
  
 
2 Table of Contents  
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .............................  4 
TERMINOLOGY  ................................ ................................ ................................ ................................ ..........................  5 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...............................  6 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................  6 
1.2 Schema  ................................ ................................ ................................ ................................ .................  8 
2 INTRODUCTION  ................................ ................................ ................................ ................................ ..........  22 
2.1 Study Rationale  ................................ ................................ ................................ ................................ .. 22 
2.2 Background ................................ ................................ ................................ ................................ .........  24 
2.3 Risk/Benefit A ssessment  ................................ ................................ ................................ ..................  27 
2.3.1  Known Potential Risks  ................................ ................................ ................................ ... 27 
2.3.2  Known Potential Benefits  ................................ ................................ ..............................  30 
2.3.3 Assessment of Potential Risks  ................................ ................................ .....................  31 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ................................ ..............  32 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ ...........  34 
4.1 Overall Design  ................................ ................................ ................................ ................................ .... 34 
4.2 Scientific Rationale for Study Design ................................ ................................ ..............................  35 
4.3 End of Study Definition  ................................ ................................ ................................ .....................  35 
5 STUDY POPULATION  ................................ ................................ ................................ ................................  36 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................................  36 
5.2 Exclus ion Criteria  ................................ ................................ ................................ ...............................  36 
5.3 Screen Failures  ................................ ................................ ................................ ................................ .. 37 
5.4 Strategies for Recruitment and Retention  ................................ ................................ ......................  37 
6 STUDY INTERVENTION  ................................ ................................ ................................ ............................  38 
6.1 Study In tervention(s) Administration  ................................ ................................ ...............................  38 
6.1.1  Study Intervention Description  ................................ ................................ .....................  38 
6.2 Study Intervention Compliance  ................................ ................................ ................................ ........  46 
6.3 Concomitant Therapy  ................................ ................................ ................................ ........................  46 
7 STUDY IN TERVENTION DISCONTINUATION AND PARTICIPANT DISCONTINUATION/ 
WITHDRAWAL  ................................ ................................ ................................ ................................ ..........................  47 
7.1 Discontinuation of Study Intervention  ................................ ................................ .............................  47 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ...............................  47 
7.3 Lost to Follow -Up ................................ ................................ ................................ ...............................  48 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................ .....................  49 
8.1 Screening & Informed Consent  ................................ ................................ ................................ .......  49 
8.2 Enrollment  ................................ ................................ ................................ ................................ ...........  51 
8.3 Safety and Other Assessments  ................................ ................................ ................................ .......  64 
8.4 Adverse Events and Serious Adverse Events  ................................ ................................ ...............  64 
8.4.1  Definition of Adverse Events (AE)  ................................ ................................ ...............  64 
8.4.2  Definition of Serious Adverse Events (SAE)  ................................ ..............................  65 
8.4.3  Classification of an Adverse Event  ................................ ................................ ..............  65 
8.4.4  Time Period and Frequency for Event Assessment and Follow -Up .......................  67 
8.4.5  Adverse Event Reporting  ................................ ................................ ..............................  67 
8.4.6  Serious Adverse Event Reporting  ................................ ................................ ...............  67 
8.4.7  Reporting Events to Participants  ................................ ................................ .................  68 
8.5 Unanticipated Problems  ................................ ................................ ................................ ....................  68 
8.5.1  Definition of Unanticipated Problems (UP)  ................................ ................................ . 68 
  
 
3 8.5.2  Unanticipated Problem Reporting  ................................ ................................ ................  69 
8.5.3  Reporting Unanticipated Problems to Participants  ................................ ...................  70 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..........  71 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .......................  71 
9.2 Sample Size Determination  ................................ ................................ ................................ ..............  71 
9.3 Populations for Analyses  ................................ ................................ ................................ ..................  71 
9.4 Statistical Analyses ................................ ................................ ................................ ............................  72 
9.4.1  General Approach  ................................ ................................ ................................ ..........  72 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  ................................ .............................  73 
9.4.3  Analysis of the Secondary Endpoint(s)  ................................ ................................ .......  75 
9.4.4  Safety Analyses  ................................ ................................ ................................ ..............  77 
9.4.5  Baseli ne Descriptive Statistics  ................................ ................................ .....................  77 
9.4.6  Planned Interim Analyses  ................................ ................................ .............................  77 
9.4.7  Sub-Group Analyses  ................................ ................................ ................................ ..... 77 
9.4.8  Tabulation of Individual participant Data  ................................ ................................ .... 78 
9.4.9  Exploratory Analyses  ................................ ................................ ................................ ..... 78 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ..............................  79 
10.1  Regulatory, Ethical, and Study Oversight Considerations  ................................ ...........................  79 
10.1.1  Informed Consent Process  ................................ ................................ ...........................  79 
10.1.2  Study Discontinuation and Closure  ................................ ................................ .............  83 
10.1.3  Confidentiality and Privacy  ................................ ................................ ...........................  83 
10.1.4  Future Use of Stored Specimens and Data  ................................ ...............................  86 
10.1.5  Key Roles and Study Governance  ................................ ................................ ..............  87 
10.1.6  Safety Oversight  ................................ ................................ ................................ .............  87 
10.1.7  Clinical Monitoring  ................................ ................................ ................................ ..........  88 
10.1.8  Quality Assurance and Quality Control  ................................ ................................ .......  89 
10.1.9  Data Handling and Record Keeping  ................................ ................................ ............  89 
10.1.10  Protocol Deviations  ................................ ................................ ................................ ........  90 
10.1.11  Publication and data Sharing Policy  ................................ ................................ ............  90 
10.1.12  Conflict of Interest Policy  ................................ ................................ ..............................  91 
11 ABBREVIATIONS  ................................ ................................ ................................ ................................ ........  92 
12 PROTOCOL AMEN DMENT HISTORY  ................................ ................................ ................................ ..... 95 
13 REFERENCES  ................................ ................................ ................................ ................................ .............  99 
14 APPENDICES  ................................ ................................ ................................ ................................ .............  104 
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
4 STATEMENT OF COMPLIA NCE  
 
The trial will be carried  out in accordance with the United States (US) Code of Federal 
Regulations (CFR) applicable to clinical studies (45 CFR Part 46 ). 
  
National Institutes of Health ( NIH)-funded investigators and clinical trial site staff who 
are responsible for the conduct, management, or oversight of NIH -funded clinical trials  
have completed Human Subjects Protection and GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant 
materials will be submitted to the Institutional Review Board ( IRB) for review and 
approval. Approval of the protocol , consent form , and Data Safety Monitoring Plan  
(DSMP) must be obtained before any participant is enrolled.  Any amendment to the 
protocol will require review and approval by the IRB before the c hanges are 
implemented.  
 
______________________________________      
Printed Name  
_______________________________________   __ __ / __ __ __ / __ __  
Signature                                      Date   
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
5 TERMINOLOGY  
Term  Definition as used in this protocol  
Infant  The research subject and proband  with signs/symptoms 
consistent with a possible genetic disorder ; in most cases the 
infant will likely be a neonate , but not necessarily    
Guardian/parent  The person who has authority to legally consent for the infant to 
participate in this research, this person may or may not be a 
biological parent . 
Biological 
parent (s), 
biological mother 
or biological father  Who is thought to be the true parent of the infant and may 
provide  a blood sample for genetic sequencing  and trio analysis; 
biological parent s participating in this study are also considered 
research subject s and may withdraw their consent at any time .  
Enrolling Site  The hospital at which the infant is enrolled into the study . 
Laboratories  Refers to Athena Diagnostics, a wholly -owned subsidiary of 
Quest Diagnostics; Rady Children’s Institute for Genomic 
Medicine – Clinical Genome Center (RCIGM -CGC) ; and Sema4 
which are conduct ing the genetic sequencing and/or 
confirmatory tests . 
Positive Result  Diagnostic findings related to phenotype - pathogenic variant(s) 
in genes interpreted to be responsible for, or contributing to, the 
infant’s phenotype ( variant classification of pathogenic or likely 
pathogenic).  
Negative Result  The result that pathogenic variants associated with the infant’s 
clinical phenotype were not detected . 
Variant of 
Unknown 
Significance  (VUS)  A variant for which the clinical significance is unknown. The 
variant detected may or may not ex plain the infant’s current 
clinical symptoms.  
Suspicious VUS  A VUS where the phenotypic fit is very good  or functional 
confirmatory tests are readily available or the results are 
actionable . 
Medically 
Actionable  There is a  preventative measure or a  treatment available to cure 
or ameliorate symptoms  and improve outcome . 
Secondary  / 
Incidental  Finding s Pathogenic or likely pathogenic mutations listed in the ACMG 59 
or in other genes unrelated to the phenotype.  Secondary 
findings are not intentionally  sought in this protocol.  The R CIGM 
laboratory report will use the term incidental findings  in order to 
emphasize that a targeted analysis for secondary findings is not 
done . The ICF will use  the term additional results . 
Provisional result  A positive result that has not been confirmed by another method .  
Final Result  Either a positive result  or VUS that is confirmed by another 
method, often Sanger sequencing /qPCR , or a negative result.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
6 1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  
 Genomic Medicine for Ill Neonates and Infants  
(The GEMINI Study)  
Study Intervention:  NewbornDx Sequencing Evaluation (NewbornDx), Rapid 
Whole Genome Sequencing (rWGS)  
Study Des cription : This multicenter, prospective clinical trial will examine the 
diagnostic yield and clinical utility of NewbornDx  and rWGS 
testing in high -risk infants with signs/symptoms consistent with 
a possible genetic disorder. Infants will undergo both 
NewbornDx  and rWGS testing  in parallel . Genetic sequences  
via NewbornDx and rWGS  will be generated for the i nfant  
(proband) and when available,  the biological parents , and 
analyzed. NewbornDx and rWGS test results will be returned 
to the infant’s clinician, medical record and parent/guardian.  
Those infants analyzed as a duo or trio will have a 
retrospective analysis done of only the infant’s data to 
determine if the same result would have been obtained with 
and without the parent samples. Clinical utility will be 
measured by clinician opinion and changes in the infant’s care 
as a result of the genetic sequencing test  results.  Quality of 
life (QoL) and medical resource utilization by parent survey 
will be collected until the infant is one year corrected 
gestational age . These data, along with a  retrospective chart 
review of infants with suspected genetic disorders , will be 
used to understand 1 -year cost and health outcomes that 
would have been incurred in the absence of the advanced 
testing. The resulting data from the trial will be used in the 
economic evaluation comparing NewbornDx , rWGS, and SOC 
over a 1 -year period and used as basis to simulate the lifetime 
cost-effectiveness of these testing strategies.  A web -based 
clinical reference database to provide references, clinical 
management guidelines, opportunities for clinical trial 
participation, and support groups for each condition will be 
developed with separate interfaces for the parent/guardian(s) 
and medical provider. The  clinical reference database  will be 
qualit atively assessed by a survey of medical providers.  
Objectives:   To estimate the diagnostic yield of NewbornDx  and rWGS  
testing  in identifying genetic disorders of unknown etiology  
 To assess the clinical utility of genomic sequencing  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
7  To examine the economic impact and health outcomes of 
NewbornDx  and rWGS  in infant s compared with SOC  
diagnostic testing , over a one -year and lifetime horizon   
 To develop and qualitatively assess the web-based clinical 
reference database of supporting information for medical 
provider s and parents  
Endpoint s: Primary Endpoint s:  
 A confirmed genetic disorder detected by NewbornDx   
 A confirmed genetic disorder detected by rWGS  
 Time  from sample collection  to positive test result   
 Clinical utility of genomic sequencing (care changes, 
time to initiation of appropriate treatment or redirection 
of care including  the withholding or withdrawing of life -
sustaining treatment ) 
Secondary Endpoints:  
 One-year cost-effectiveness of SOC, NewbornDx  and 
rWGS  testing   
 Lifetime cost -effectiveness of SOC, NewbornDx  and 
rWGS  testing  
 User satisfaction with the clinical reference database  
Study Population:  400 infants less than one year corrected gestational age 
(CGA ) admitted to a hospital (NICU/PICU/ CICU/inpatient 
floor) participating in this study with signs/symptoms 
consistent with a possible genetic disorder  
Phase:  N/A  
Enrolling Sites : The Floating Hospital for Children at Tufts Medical Center, 
Cincinnati Chi ldren's Hospital Medical Center, Mount Sinai - 
Kravis Children’s Hospital, Children’s Hospital of Pittsburgh, 
Rady Children's Hospital - San Diego, and North Carolina 
Children's Hospital  
Study Duration:  54 months  
Participant 
Duration:  
 From enrollment until 1 year CGA  
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
8 1.2 SCHEMA  
  
Enroll in R EDC ap system  Urgent Testing Determination  Part 1: Screening and Enrollment  
Informed consent  Screening  
Upload Redacted ICF to R EDC ap Blue = Enrolling site  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
9   
Add Sample ID#s and ship 
to Athena and RCIGM  Part 2: Sample Collection and HPO  
Obtain blood samples and label 
with Name and DOB  
Mount 
Sinai 
Subject?  Yes  No Order rWGS in the  
RCIGM Portal  
Sema4 extracts DNA, 
ships to RCIGM  Add Sample ID#s and ship 
to Athena and Sema4  Complete Athena 
NewbornDx  Paper 
Requisition  
Site extracts phenotype, 
uploads HPO terms to 
RCIGM ordering portal  Blue = Site  
Green = Sema4  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
10   
NewbornDx  
Primary 
pathogenic, likely 
pathogenic or 
suspicious VUS?  
No Yes  
Send primary 
provisional result 
for confirmation 
testing  Provide provisional 
result with 
management 
guidance  Part 3: NewbornDx /rWGS Tests  
Enrolling site 
(except Mount 
Sinai) returns 
provisional 
result to 
clinician/parents
/MR  Athena  RCIGM  
Blue = Enrolling site  
Orange = Athena  
Purple = RCIGM  
Provisional 
reporting?  
No Yes  rWGS  
Primary 
pathogenic, likely 
pathogenic or 
suspicious VUS?  
Yes  No 
Send primary 
provisional result 
for confirmation 
testing  Provide provisional 
result with 
management 
guidance  Provisional 
reporting?  
Yes  No 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
11   
Secondary Infant 
Finding?  
Yes No Part 4: Secondary Findings for the Infant  
Yes No 
Yes No Opt-in for infant 
secondary finding?  
Disorder onset in 
childhood?  
Medically actionable 
or ACMG59?  
Yes No 
Don’t Report  Secondary Infant 
Finding?  
No Yes 
No Yes 
No Yes Opt-in for infant 
secondary finding?  
Disorder onset in 
childhood?  
Medically actionable 
or ACMG59?  
No Yes RCIGM  Athena  
Send infant secondary 
finding for confirmation 
testing  Send infant secondary 
finding for 
confirmation testing  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
12   
Athena will not 
report secondary 
findings for a 
parent  
Don’t Report  Part 5: Secondary Findings for a Biological Parent  
Athena  
Secondary finding for a parent?  
Opt-in parent secondary findings?  
Send parent secondary finding for 
confirmation testing  On the ACMG59 List?  No Yes  No Yes  
No Yes  RCIGM  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
13  
 Part 6: Confirmation Testing  & Return of Results  
Athena  RCIGM  Orange = Quest  
Purple = RCIGM  
Athena conducts confirmation 
testing  RCIGM conducts confirmation 
testing  Findings to 
confirm?  
No Yes  Findings  to 
confirm?  
Yes  No 
Athena sends CLIA -
certified final report for 
infant to enrolling site and 
Tufts  RCIGM sends CLIA -
certified final report(s) for 
infant and if applicable, 
parent, to site and Tufts; 
(exception: RCIGM 
workflow for Mount Sinai 
subjects shown in Part 7)  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
 
14  
Luci dchart
Part 7: RCIGM Workflow for Subjects from Mount Sinai Only. All other sites proceed  to Part 8.  
This workflow will be eliminated when  rWGS becomes New York State approved  
 
 
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
15  
  
Concordant 
results?  
Adjudication 
Procedures   Enrolling site and Tufts MC co-PIs and Project Manager 
receive confirmed results  
No Study Workflow Part 8 - Reconciliation of Results  
Enrolling site informs clinician and guardian of final 
results, documents how results will be used in clinical care 
(all CLIA certified lab reports, even if discordant, remain in 
infant ’s medical record);  
Site returns any secondary findings to biological parent 
after confirming opt -in; refers to adult genetics  Blue = Enrolling site  
Gray = Tufts  
Yes  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
16  Study Workflow Part 9 – Adjudication Procedures  
 

Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
17   
Final parent interview and QoL instruments at 1 
Year CGA  After discharge home, monthly parent survey and 
QoL instruments every 3 months  Physician clinical utility survey  
Chart abstraction of clinical actions  Part 9: Post Result through 1 Year CGA  
Blue = Enrolling site  
At transfer or discharge home, obtain follow -up 
contact information , complete QoL instruments, 
upload redacted source documents to R EDcap  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
18 Schedule of Activities (SoA)  and Data Case Report Form s A= Athena (Quest) , 
R=RCIGM, S4=Sema4  
Procedures  
Screening  
Enrollment  
Genetic Sequencing  
Return of  final result  
Transfer  to facility  
Discharge home  
Follow -up #1 -11 
1 year CGA  
Site Evaluate inclusion /exclusion criteria   X        
Site Consult c linical genetics or specialty service  per SOC  X        
Site Informed consent process  X        
Site Complete screening log  X        
Consented and Enrolled Infant s 
Site Enroll infant  in REDCap   X       
Site Determine if the infant requires urgent testing    X       
Site Obtain blood samples for infant  and biological parent (s)  X       
Site Order rWGS  (or Ultra Rapid for Urgent Cases)  in the RCIGM 
portal;  indicate secondary finding elections for infant and each 
biological parent    X       
Site Complete Athena  Laboratory requisition  for NewbornDx , 
indicate infant secondary finding election    X       
Site Notify Athena of need for urgent testing, if applicable   X       
Site Ship samples  to Athena  Diagnostics and RCIGM (or Sema4 *)  X       
Site Scan redacted ICF signature pages into REDCap    X    X  X 
Site Provide clinical information and HPO terms  to RCIGM portal  
and Athena    X      
A Complete NewbornDx  [duo/trio if parent sample(s) are 
available ]   X      
R Complete rWGS  [duo/trio if parent sample(s) are available ]    X      
A, R Return verbal provisional result , if applicable,  with 
management guidance to enrolling site clinical staff*, site PI , 
study -wide Co -PI     X      
Site Enter provisional result , if applicable,  with management 
guidance as a research note to infant ’s medical record and 
notify the infant’s parent/guardian s   X      
A, R, S4  Complete confirmation testing  for pathogenic , likely 
pathogenic  and suspicious VUS findings*   X      
A, R, S4  Return  final infant result  to enrolling site research team  and 
study -wide co -PIs/project manager      X     
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
19 A= Athena (Quest) , 
R=RCIGM, S4=Sema4  
Procedures  
Screening  
Enrollment  
Genetic Sequencing  
Return of  final result  
Transfer  to facility  
Discharge home  
Follow -up #1 -11 
1 year CGA  
R, S4  Return confirmed parental secondary findings to  the enrolling 
site if  applicable and  the parent opted in on  the ICF*    X     
Site Return  the final result for the infant  to the clinical team , 
infant ’s medical record  and the infant’s parent/guardian s    X     
Site Notify the biological parent of confirmed secondary findings , if 
applicable and  that parent opted in on ICF     X     
Tufts , 
Site Follow adjudication procedures  if the final results from 
NewbornDx  and rWGS are discordan t or if Sema4 does not 
confirm the rWGS  result     X     
Site Administer clinical utility survey      X     
Site Obtain hospital bill (s) for infant  hospitalization during which 
the research testing occurred      X X   
Site Obtain the parent/guardian  contact information for follow -up      X X   
Site Administer parent SF -12 QoL and child visual analog scale       X X X 
Site Administer  or if completed by email, review the  
parent/guardian  Resource Utilization  monthly interview      X X X X 
Site Obtain medical records  as necessary  (i.e. a new diagnosis or 
adverse event)       X X X 
A, R, S4  Monitor for non -conforming events or errors    X X     
Site Monitor for adverse events   X X X X X X X 
Site Monitor for protocol deviations    X X X X X X X 
*Mount Sinai will send blood samples  for the infant  and each biological parent  to Sema4 instead of RCIGM. 
Sema4 will extract the DNA, save one aliquot for future confirmation testing and ship one aliquot to RCIGM . 
Test results that are reported by RCIGM rWGS will be treated as research results for subjects from Mount 
Sinai. Results from RCIGM rWGS will be placed in the infant’s research file and not the infant’s medical 
record. Positive and VUS results reported by RCIGM that are not also reported by Athena Diagnostics will 
be confirmed by Sema4 and a Sema4 laboratory report will be placed in the infant’s medical reco rd. The 
protocol allows for the return of a provisional result when a treatment is available and waiting for 
confirmation testing puts the infant at irreversible harm. Provisional results will not be given for subjects from 
Mount Sinai when the provisional  result is found only by RCIGM rWGS. A provisional result may be given 
for results from Athena Diagnostics NewbornDx . 
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
20 Electronic Case Report Form Submission Schedule   
[X] =Data reported as applicable  
Data Case Report Forms  Time point  Screening  
Enrollment  
Return of 
Result  
Transfer 
and/or 
Discharge 
Home  
Follow -up 
#1-11 
1 Year 
CGA  
  Forms Required for All Subjects Approached  
Demographics  X      
System(s)  X      
Consent  X      
 Forms Required for All Subjects Enrolled  
Enrollment   X     
Urgent Testing   X     
Source Documents   X X [X] [X] [X] 
Prenatal History   X     
Birth History   X     
HPO   X     
Specimens/Results   X X    
Results Concordance    X    
Clinical Utility Survey    X    
Clinical Actions    X    
Transfer/Discharge     X   
Child -Visual Analog Scale     X X1 X 
SF-12    X X1 X 
Hospital Bill     X   
CPT    X   
Resource Utilization Survey      X X 
Completion   [X] [X] [X] [X] X 
 Forms Required for All Subjects Enrolled  as applicable  
Clinical Genetic Tests   [X] [X] [X] [X] [X] 
Newborn Screening   [X] [X] [X] [X] [X] 
Medications   [X] [X] [X]   
Surgeries   [X] [X] [X]   
Death   [X] [X] [X] [X] [X] 
Adverse Event   [X] [X] [X] [X] [X] 
Protocol Deviation   [X] [X] [X] [X] [X] 
1The Child -Visual Analog Scale and SF -12 are completed at discharge home, then every 3 months and at 1 -year 
CGA.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
21 Other forms utilized by the enrolling site   
Screening  
Enrollment  
Return of result  
Transfer and/or 
Discharge home  
Follow -up #1 -11 
1-year CGA  
Site Screening and Enrollment Log  X      
Demographics Source Document*  X      
Documentation of Informed Consent*   X     
Eligibility Checklist*   X     
Informed Consent Checklist*    X     
Documentation of Informed Consent for the Medical Record *  X     
Blood Specimen Collection Source Document *  X     
HPO Source Document*   X     
Athena Diagnostics Laboratory Requisition   X     
RCIGM Laboratory Requisition (printed from RCIGM portal)   X     
Sema4 Laboratory Requisition (Mount Sinai only)   X     
Documentation of Verbal Result*     X    
Parent/Guardian Contact Information Form      X   
Documentation of Follow -up *     X X 
Study Workflow Checklist *   X X X X X 
 *Optional use by site if other source documentation or site -specific forms exists  
 
Data sent from each laboratory; data stratified by infant  case ID (RCIGM) , accession number ( Athena ) 
or sample ID .  
Preliminary result [gene(s) and variant(s)] prior to confirmation testing  
Date and time of sample receipt  
Date and time the preliminary result  was determined  prior to confirmation testing  
If the preliminary result was returned provisionally, the d ate/time the verbal  result was called to the site  
If the preliminary result was returned provisionally, the date /time the provisional written report was  sent 
to the site 
Whether the preliminary result was determined using proband -only, duo or trio  data 
Whether or not the confirmation testing confirmed  the preliminary result  
Infant -only analysis for subjects who were initially analyzed as a duo/trio    
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
22 2 INTRODUCTION  
 
2.1 STUDY R ATIONALE   
 
Congenital abnormalities and genetic disorder s are a leading cause of infant mortality in 
the US1. While  newborn screening (NBS) has dramatically reduced infant morbidity and 
mortality for some genetic disorders, these improvements have not had a significant 
impact in Neonatal Intensive Care Units (NICU) where 10 -25% of all NICU admissions 
are the result of a  genetic disorder . Infants with a genetic disorder remain in the hospital 
approximately 40% longer than those without genetic disorders . Due to the non -specific 
presentation of many of these genetic disorders, many infants do not receive a definitive 
diagn osis in a timely fashion, if at all.  
 
Undiagnosed genetic dis orders  contribute significantly to infant mortality and morbidity. 
Each year, an estimated 14.4% of neonates are admitted to the NICU for treatment of 
an acute condition, with average medical co sts of $76,164 per patient. Overall mortality 
rates in the NICU vary from 0.8% to 6.2%, increasing to as high as 57% when there are 
significant delays in appropriate diagnosis3-5. Genetic abnormalities (e.g. structural and 
metabolic disorders) are a leading cause of death in these infants with over 8,500 
known genetic dis orders  as major contributors5-15. While we do not yet know the genetic 
basis of many disorder s in neonates , it has been estimated that more than 1,900 genes 
appear to be relevant in the neonatal period with symptom onset generally occurring 
prior to 2 years of age. Until the recent development of rWGS, timely molecular 
diagnosis of many suspected genetic disorders did not occur. In fact, preliminary studies 
demonstrate that neonates with a genetic disorder risk going undetected or being 
misdiagnosed, with 45% of diagnoses made via rWGS not included in the clinician's 
initial differential diagnosis16. The result can be a 5-year gap between disorder  onset 
and diagnosis due to: 1) profound clinical and genetic heterogeneity; 2 ) limited  standard 
genetic testing currently available (e.g. sequential and single gene sequencing); 3) 
prolonged length of time required to obtai n the results of standard genetic tests; and 4) 
deferral of testing to post discharge since most payers do not reimburse hospitals for 
genetic testing while a neonate remains hospitalized17-22.  
 
When performed early in the clinical course, rWGS  triple s the diagnostic rate compared 
to SOC23, 24. This provides preliminary evidence that rWGS or NewbornDx  could be 
more cost effective and clinically useful  than current standard of care  (SOC)25. 
Furthermore, data from the NSIGHT study ([STUDY_ID_REMOVED]) indicates a  diagnosis is 
made only 15% of the time in the neonatal period using  SOC testing compared to 44% 
for rWGS70. The total  cost for clinical r WGS trio is ~ $19,500,25,26 suggesting that 
NewbornDx  panel followed by a reflex to rWGS (if necessary) may be a more optimal 
use of resources25,28 -31. Here we propose to examine the diagnostic yield of NewbornDx  
and rWGS , assess the clinical utility  of genomic testing , and evaluate each technique’s 
relative cost using data collected from the trial along with  simulation  modeling . The NIH, 
the National Academy of Medicine (NAM ), and several European agencies have 
consistently identified scientific and operational barriers to implementation of genomic 
medicine. Specifically, the “burden to clinicians in obtaining, interpre ting, and managing 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
23 results”, including “integrating effective clinical decision support tools into the EMR” are 
some of the biggest challenges of scaling genomic medicine32-35.  
NewbornDx  offers many  of the benefits of rWGS  by: 1) detecting some non-exonic  
regions, sequence variants, chromosomal level abnormalities and high homology 
regions; 2) covering multiple phenotypes; 3) improving interpretability; 4) lowering costs; 
5) obtaining  relatively  rapid  results and 6) expanding utilization worldwide (potenti ally 
conducting the panel on every neonate as the next generation of NBS ). NewbornDx  and 
rWGS  also offer future opportunities to incorporate other features such as the ability to 
detect variants that alter protein abundance, initiation codons, stop codons and triple t 
expansion repeats. These future enhancements will assist neonates who currently 
cannot be confirmed as positive when there is a single heterozygous pathogenic variant 
in an autosomal recessive disorder  and a second variant cannot be detected.  However, 
unlike   rWGS, NewbornDx  will not include newly discovered disorder  genes  (although 
they can be added in the future) . rWGS is more comprehensive and covers large r areas  
of the genome allowing examination of intronic regulatory variants compared to 
NewbornDx . It is therefore very timely to understand the  diagnostic  yield of rWGS and  
NewbornDx , the cli nical utility of rapid genomic testing , and the cost -effectiveness of the 
approaches  compared to each other and the current standard of care . 
Since disorder progression can be extremely rapid in neonates, a molecular diagnosis 
must be made as soon as possible  in order to impact outcome19,20,24,26,33,34. Stark, et.al 
performed a study supporting the utilization of molecular diagnostic platforms to improve 
outcomes, reporting a 58% diagnostic rate in neonates who underwent WES compared 
to a 17% diagnostic rate in neonates who underwent standard genetic inve stigations23. 
Despite the se high-yield diagnostic rates, the average time -to-molecular diagnosis using 
conventional WGS and WES is prolonged (>3 -4 weeks), limiting their clinical utility. In 
particular, neonates receiving an early molecular diagnosis (37%)  did better than those 
diagnosed later (20%). Initiation of palliative care and avoidance of major morbidity 
were higher among those with an early diagnosis (17%) compared to those with a later 
diagnosis (9%). Overall, these studies suggest that outcomes c an be significantly 
improved with earlier diagnosis (similar to NBS). NBS identifies 12,500 affected babies 
per year at <10 days of life or about 0.3%35. Although r apid diagnosis through NBS is 
known to save thousands of lives per year, it represents just a small fraction of the 
genetic disorder  burden in neonates and is limited to detection of protein levels using 
Tandem Mass Spectroscopy . In addition,  these protein levels are often adversely 
affected by the treatments delivered in the NICU such as total  parenteral nutrition. By 
enhancing  diagnostic yield, cost -effectiveness , and time to diagnosis, NewbornDx  or 
rWGS  could facilitate more rapid initiation of appropriate therapeutic interventions or 
redirection of the goal of care from cure to comfort and/or the withdrawing of life -
sustaining treatment5,24,36 -41. The goal of a precision medicine approach in the NICU is 
to apply rapid molecular diagnostics in order to supplement empiric, phenotype -driven 
management with genotype differentiated treatments.  
 
Innovation  
 The NewbornDx  panel covers 98.4% of the genes in which sequence variants 
may cause known neonatal onset phenotypes.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
24  The NewbornDx  panel , like rWGS,  offers opportunities for future improvements 
through the addition of newly discovered genes as well as the development of 
features that allow genome enrichment on the protein level that are 
complementary to NBS.  
 Simple clinical reporting formats have been developed where results can be 
delivered electronically to the point of care through the EMR and easily 
referenced for future use.  
 Our approach will establish interoperability and scalability across all healthcare 
institutions even where genetics expertise may be limited. This critical step 
towards implementation is vital since the vast majority of ne onates are admitted 
to NICUs where there may be limited access to experts in Medical Genetics . 
 The incorporation of NewbornDx  or rWGS  into neonatal care does not have to 
impact the infant ’s future with information regarding possible  later adult onset 
diagn oses.  
 This prospective, multicenter trial will provide the first prospective comparison of 
NewbornDx  and rWGS in NICUs with long-term follow -up to elucidate risks vs. 
rewards, costs vs. benefits, and impact on morbidity and mortality.  
 Neonates at the six CTSI sites are ethnically and racially diverse, which will 
address ongoing criticism of existing rWGS  trials that lack sufficient ethnic/racial 
diversity to insure generalizability.  
 
2.2 BACKGROUND   
 
In-silico comparison of 
diagnostics rates demonstrate 
that a rapid neonatal 
NewbornDx (aka TNGS ) panel 
may detect up to 90% of the 
same disorders as WGS at 
substantially lower cost ( Figure 
1).  
 
We performed a retrospective in 
silico comparison of the 1,722 
gene NewbornDx  panel to 
already published rWGS and 
rWES clinical data from three 
studies representing 67  patients 
and 75 variants19,20,33. 
Compared to WES/WGS, the 
NewbornDx  panel would have de tected 85 -94% of the same variants. A rapid 
NewbornDx  panel using DBS has already been clinically validated under an SBIR 
Phase I grant through NICHD42. The panel is available as a laboratory developed test 
and is composed of 1,722 genes representing disor ders that affect all systems ( Figure 
2), including all coding regions and clinically relevant non -coding regions.  

Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
25 Figure 2. NewbornDx  panel representing all 16 systems  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The phenotypes for most of these disorders typically present before 2 years of age. 
Specifically, of the 2,300 genes with neonatal onset phenotypes in OMIM, 1,750 are the 
result of sequence variants (76%) and 150 are the result of copy number variants 
(CNVs ) (6%). There are an additional 150 tumor cell line genes (7 %) and 250 genes 
(11%) with benign phenotypes. Eliminating the latter two groups leaves 1,900 genes 
with neonatal onset phenotypes, from which we have curated the final list of 1,722 
genes while eliminating portions of the genome that are challenging to se quence on any 
platform. The result is a comprehensive NewbornDx  panel that represents 98.4% of the 
known genes in which sequence variants result in disorders presenting in the neonatal 
period ( Figure 3 ).  Audiological  
Hearing loss (syndromic): 127 genes  
Structural abnormalities: 24 genes  
 
Cancer Predisposition  
Neuroendocrine/CNS: 22 genes  
Hematologic: 50 genes  
 
Metabolic  
Mitochondrial: 132 genes  
Carbohydrate metabolism disorder: 23 genes  
Lysosomal storage disease: 38 genes  
 
Neurological  
Brain malformations: 196 genes  
Seizures: 304 genes  
Microcephaly: 266 genes  
 
Hematologic  
Anemia: 82 genes  
Bleeding disorder: 29 genes  
Platelet disorder: 35 genes  
 
Gastrointestinal  
Large and small intestine: 10 genes  
Liver disease: 42 genes  
Failure to thrive: 18 genes  
 
Skeletal  
Short stature: 84 genes  
Contractures: 31 genes  
Bone fragility: 29 genes  
 
Respiratory  
Respiratory distress: 39 genes  
Abnormal breathing: 12 genes  
 Muscle  
Muscle atrophy/dystrophy: 44 genes  
Hypotonia: 81 genes  
 
Skin  
Abnormal pigmentation: 25 genes  
Abnormal hair and hair growth: 18 genes  
Blistering: 18 genes  
 
Endocrine  
Adrenal dysfunction: 15 genes  
Hypo -/hyper -glycemia: 44 genes  
Hyper -/hypo -parathyroidism: 32 genes  
 
Immune  
Recurrent fever/recurrent infections: 18 genes  
Immunodeficiency: 56 genes  
 
Cardiac  
Cardiomyopathy: 106 genes  
Structural defects: 108 genes  
Conduction defects:  107 genes  
 
Genitourinary  
Renal disease: 115 genes  
Genital abnormalities: 37 genes  
 
Ophthalmologic  
Abnormal eye movements: 46 genes  
Anterior chamber dysgenesis: 27 genes  
Optic nerve abnormalities: 42 genes  
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
26  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ability of NewbornDx  to detect CNVs increases this number to 98.5% of total genes 
known to cause neonatal disorders. The panel shows analytic sensitivity of 98% for 
single nucleotide variants with an average depth of coverage of 139x (>97% of bases 
are covered at 20x). Extraction of DNA from DBS has also been validated and can be 
performed using an existing sample collection kit.  
 
In preliminary studies, NewbornDx  compared favorably to rWGS, an d SOC . We 
performed NewbornDx  on 10 trios from Pittsburgh's Children’s Hospital (our collaborator 
Dr. Vockley) and 6 patients from Rady Children’s Hospital (Dr. Kingsmore). Neonates 
were chosen based on the clinical suspicion  of an underlying genetic condi tion with 
symptom onset early in life. Results were returned within an average of 13 days. We 
found 7 patients with causative variants for a diagnostic yield of 47%, in line with that 
observed in previous publications using WES and WGS. One of the diagnoses was a 
condition not included in the pre -test differential diagnosis, consistent with the findings 
in Petrikin et al.16. Results from Dr. Kingsmore’s study ([STUDY_ID_REMOVED]) suggest 
NewbornDx  may have detected 100% of diagnostic findings generated usi ng WGS33. 
 
There is a strong need for prospective studies examining the clinical utility of 
NewbornDx    and rWGS in neonates . While studies have compar ed WES/WGS in the 
NICU, they lacked generalizability to a larger population since: 1) they were 
underpowe red or were not prospective, 2) patients were selected based on a positive 
family history, or 3) the variants were detected in previously characterized genes and 
therefore potentially detectable on the NewbornDx  pane l, 4) they did not utilize recently 
Figure 3: Contribution of variant types to condi tions with neonatal -onset 
presentations.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
27 deve loped rapid methods for rWES or rWGS24,25,27,33,43. As such, no prospective 
assessment of the clinical utility, cost -effectiveness or outcomes associated with a 
NewbornDx -based diagnosis of genetic disorder s has been conducted. Such evidence 
is critical to justify the use of the methodology given the cost limitations imposed for 
hospitalized neonates (inpatient genetic testing is expensive, often bundled, and usually 
not reimbursed independently). In particu lar, no study has examined the temporal 
dynamics of genetic disorder  progression in the most vulnerable neonates and defined 
specific metrics to evaluate how NewbornDx  and/or rW GS will best guide treatment and 
reduce morbidity and mortality. Finally, there  are limited studies defining best practices 
related to NewbornDx  or rWGS with regard to communicating information to the medical 
team and family. This includes : 1) providing timely results with appropriate genetic 
counseling, 2) review ing information  abou t available clinical trials and/or approved drugs 
to treat the condition, or 3) offering redirection of care from cure to comfort and/or 
withdrawing of life -sustaining treatment . We propose a prospective study of the 
effectiveness of NewbornDx  and rWGS in infants admitted to the hospital  with a 
suspected genetic disorder. This transformative study represents one of the first times 
key stakeholders with expertise in neonatal clinical trials, medical genetics, and 
molecular diagnostics are participatin g in a prospective study of this size and scope.  
 
2.3 RISK/BENEFIT ASSESSM ENT   
 
2.3.1  KNOWN  POTENTIAL RISKS  
 
Blood Sampling : Blood samples should pose minimal health risks to participants. Every 
attempt will be made to obtain blood  from the enrolled infant  at the time that routine 
samples are collected for clinical indications. For the infant , a minimum of two and a 
maximum of five dried blood spot s are needed for NewbornDx , a total blood volume of 
1mL for rWGS . This one-time blood sample from the infant  should not cause undue 
trauma or excessive blood loss. If the clinical team does not feel it is safe to obtain  the 
sample  from the infant , then we will obtain the blood just prior to a packed red blood cell 
transfusion.  The 3ml of blood  from each biologic al parent is considered minimal for an 
adult. Risks associated with blood draws are usually minor and include pain, anxiety, 
bleeding, bruising, fainting, and rarely infection at the site. All sample s will be  collect ed 
by qualified staff following hospital guidelines and standard precautions.    
 
Loss of confidentiality : Since we are storing identifying information about the infant  and 
parents , there is a small risk that this information may be compromised . All study rel ated 
material will be stored securely. Each enrolled infant  will be assigned a unique study 
identification number w hich does not include any identifiers . Infant  information entered 
into the  password -protected REDCap  System and documents used for remote 
monitoring will be identified by the study ID number. Each site will keep t he link between 
the study ID number and identifiers for all subjects enrolled at their site in a secure 
password -protected spreadsheet . Blood samples , medical information provided on the 
laboratory requisition form, sequencing data , and result s from the laborato ry will be 
identifiable by name  and date of birth . This is to ensure that: 1) the correct infant can be 
identified immediately 24/7 in the case of a time sensitive result that could influence 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
28 survival and outcome; and 2) to eliminate any errors with matching of study ID to infant 
at the enrolling site. The ICF clearly indicate s that the labeling of specimens , medical 
information , and reports to/from the laboratories will contain identifying information. All 
genomic sequencing data will be electronically stored at the laboratory that conducted 
the test in pa ssword -protected databases accessible only to research personnel. In 
addition, this study is automatically issued a COC. PHI related to a genetic diagnosis 
may need to be shared with government agencies or other organizations involved in the 
research. WGS may uniquely identify any person. Since a COC may not apply in all 
circumstances  and WGS can identify any person , it is essential that this be included in 
the ICF.  
 
Secondary findings  for the infant and biological parent (s): NewbornDx  and rWGS may 
detect  secondary findings . These include  diagnoses  for the infant or a biological parent  
not related to the infant ’s symptoms, misattributed parentage , and suspected incest . 
Parents /guardians  of infant s will be counseled prior to enrollment about the information 
available from each platform.    
 
The infant’s parent/guardian will choose whether or not to receive secondary diagnoses 
for the infant. This will be by an opt -in or opt -out (express choice of o ne or the other) 
included in the ICF.  A secondary diagnosis for the infant  will only be reported if both 
criteria 1 and 2 are met and at least one of 3a  or 3b:  
1. The parent/guardian opted to receive secondary findings for the infant , AND  
2. The disorder onset may occur in childhood , AND  
3. At least one of the following:   
a) The disorder is medically actionable  AND/OR  
b) The disorder involves a gene on the  “American College of Medical Genetics 
and Genomics  (ACMG ) list” of genes recommended for reporting of 
secondary findings  at the time of testing46  
 
It is possible a secondary diagnosis will eventually become a primary diagnosis (in the 
case where the infant has not yet grown into the phenotype , an atypical presentatio n, or 
the field advances) and the parent/guardian will not have been given the relevant 
information because the parent/guardian elected not to receive secondary findings for 
the infant. Information about conditions with an onset occurring only in adulthood  will not 
be given for the infant.   
 
If the parent/guardian opted -in for infant secondary findings, a biological parent  will have 
the choice to opt -in on the ICF to receive secondary findings. A secondary diagnosis for 
a biological parent will only be reported if the biological parent  opted in to receive 
secondary findings and the  disorder i nvolves  a gene on the ACMG list recommended to 
report as secondary findings at the time of testing . There are some circumstances in 
which a biological p arent  of an infant could learn about a current condition or an 
increased risk for an adult -onset disorder even if they do not opt -in to receive secondary 
findings by the inheritance and penetrance pattern of the infant’s disorder.   
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
29 Misattributed parentage  (mistaken paternity or an egg donor)  will not be reported  by the 
laboratory  or the enrolling site . The ICF indicate s that misattributed parentage could be 
inferred from the results. For example, the infant is found to have an autosomal 
recessive condition  and one parent is found not to carry this condition and de novo 
mutation s are known to be rare. Additionally, the ICF state s that there are privacy risks 
if the parent /guardian and/or biological parent  receives the raw sequencing data and 
gives it to another person  for analysis . Privacy risks which include misattributed 
parentage will be explained if a parent/guardian requests to receive raw sequencing 
data.  
 
This testing could detect incest, defined as “ a sexual relations hip between people too 
closely  related to marry each other (such as a person having a sexual relationship  with 
a parent, grandparent, brother, or sister). ” If incest is suspected, this information will be 
reported to the site. The site will notify child protective services. Risks of di scovering 
and reporting incest may include possible criminal charges depending upon state law.  
Risks to the infant include behavioral problems and removal from the home . The 
capability of the sequencing tests to detect incest , the legal requirement to report it to 
child protective services and associated risks is in the informed consent form.  
 
The ICF state s that secondary findings in the infant or biological parents is not the 
primary purpose of this research study and just because a secondary finding isn’t 
reported doesn’t mean any disease -causing genetic changes  don’t exist . 
 
Misinterpretation of result s: We expect to miss a small number of structural variants  
(SVs) using short read rWGS  (NewbornDx  does not detect structural variants)  that are 
causal. We will monitor the percentage of identified SVs and be careful not to label 
cases with a negative result as not genetic in origin. Experienced personnel will perform 
the genomic testing according to w ell-established protocols. Although we may not find a 
result , this does not mean the infant  will not continue to have symptoms  or even have a 
genetic disorder . Similarly, the infant ’s health may not improve during this study; it may 
get worse or stay the same. All infant s will continue to receive routine care as directed 
by the clinical team , including routine  NBS and other genetic testing.  
 
Risk of discrimination associated with gen etic testing : Federal and State laws generally 
make it illegal for health insurance companies, group health plans, and most employers 
to discriminate against a person based on their genetic information. The Genetic 
Information Non -discrimination Act (GINA)  indicates that genetic information cannot be 
used by certain health insurance companies when making decision s about eligibility for 
health insurance or how much insurance costs. These insurance companies can still 
use any genetic information to help them decide whether or not they will pay health 
insurance claims. This law also indicates that employers with fifteen or more employees 
may not use genetic information when making decisions to hire, promote, or fire an 
individual or when setting the terms of em ployment. Protections by this law may not 
apply to certain military, veterans and federal employees. These laws do not protect 
against genetic discrimination by companies that sell life, disability, or long -term care 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
30 insurance. Information regarding the pr otections and limitations of Genetic Information 
Nondiscrimination Act (GINA) will be included in the ICF.  
 
Emotional distress : Genetic testing may cause anxiety or emotional distress due to 
feelings of responsibility for passing genetic variants to children. If parents/guardians 
and/or biological parents opt -in to receive secondary findings for their infant  and/or 
themselves, this  information may improve their overall health, but could provoke anxiety 
by knowing the information. Genetic  counselors will be available to all 
parent/guardian(s) and/or biological parents  at all times while enrolled in the study to 
answer questions or  addressing  concerns related to testing or results.  
 
2.3.2  KNOWN POTENTIAL BENE FITS  
This study may or may not benefit the infant. A n infant may receive a diagnosis or 
additional information regarding his or her medical condition. The main benefit s to the 
infant i nclude  a faster time to diagnosis , a more accurate diagnosis , and  initiation of 
appropriate interventions faster than possible with standard diagnostic testing. These 
benefits have the potential to significantly reduce morbidity, mortality, other diagnosti c 
testing, overall hospital costs , and time to initiate appropriate treatment and time to 
discharge. There will be no direct benefit to participation for unaffected family members 
except where a diagnosis provides information regarding reproductive decisio ns and 
recurrence risks. The targeted nature of the NewbornDx  testing enables reporting of 
results without providing secondary findings that might burden families.  
The NewbornDx  panel and rWGS may each have specific benefits including:  
 NewbornDx  only detects variants in genes known to be actionable in the 
neonatal period.   
 NewbornDx  avoids the financial burden of rWGS.  
 NewbornDx  decreases the ethical considerations of rWGS related to secondary 
findings or findings related to parents; however, t hese findings can be associated 
with improved health for patients and families.  
 Rapid return of results (either by rWGS and/or NewbornDx ) 
 rWGS provides coverage of CNVs and other genetic disorders  
Importance of the knowledge to be gained:  
rWGS is slowly becoming integrated into neonatal care in an attempt to broaden 
diagnostic coverage while reducing time to diagnosis. However, each platform is 
expensive, may identify disorders with limited therapeutic options, and uncover adult 
onset disor ders. NewbornDx  adopts the philosophy of NBS by providing assessment of 
1,722 genes matched to phenotypes presenting in the neonatal period, including those 
where a timelier intervention can improve outcome. Our preliminary data indicate that 
NewbornDx  may be superior to traditional diagnostic testing and genome scale 
sequencing by transforming empiric, phenotype -driven management into genotype -
informed treatment plans that improve outcome without the ethical, financial and 
technical burdens associated with  WGS. If NewbornDx  has a comparable diagnostic 
yield as rWGS, with favorable cost effectiveness compared with rWGS and standard of 
care, it could easily be adopted worldwide. This study has the potential to advance the 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
31 expanding field of molecular diagnosi s in high -risk neonates and even enhance 
traditional NBS.  
2.3.3  ASSESSMENT OF POTENT IAL RISKS 
 
 Drawing of blood can be associated with pain, bruising, anemia, and possible 
infection . 
 A genetic diagnosis could be missed, with clinicians thinking it is unlikely to  be 
present since the genetic testing is negative . 
 If parents/guardians and/or biological parent s opt -in to receive secondary findings for 
their child and/or themselves, this information may improve their overall health , but 
also may provoke anxiety in learning about the information . 
 If parents/guardians and/or biological parent s opt-out of receiving secondary 
findings , they will not receive information that could potentially imp act their health or 
their child’s health . 
 Despite the presence of a COC, PHI re lated to a genetic diagnosis may need to be 
revealed to government agencies or other organizations involved in the research . 
 For a critically ill infant , a preliminary diagnosis may be disclosed to the clinical team 
without time for confirmatory testing. Potential therapy may be initiated that may not 
be necessary.  
 If a diagnosis is made, the information  may not  be provided to the clinical team in 
sufficient time to improve outcome . 
 It is not clear how reporting o f variants of unknown significance will imp act care and 
outcome . 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
32 3 OBJECTIVES AND ENDPO INTS  
Primary Objectives  Endpoints  Endpoint 
Justification  
To estimate the 
diagnostic yield of 
NewbornDx  and 
rWGS in identifying 
genetic disorders of 
unknown etiology  Primary  A confirmed genetic disorder 
detected by NewbornDx   
A confirmed genetic  disorder 
detected by rWGS  Assess diagnostic 
capability of the 
platforms  
Secondary  For diagnoses by rWGS, if 
trio testing was required to 
confirm a diagnosis  Assess need for 
including 
biological parent s 
To assess the clinical 
utility of genomic 
sequencing   Primary  Time from sample collection 
to positive  test result  Assess the 
timeliness of a n 
accurate  result  
Primary  Clinical utility of genomic 
sequencing  Assess impact on 
care 
Secondary  If the infant  does not receive 
a diagnosis , calculated at 
discharge and at 1year  CGA  Assess the 
clinical impact of 
platform(s)  
Secondary Objectives  Endpoints  Endpoint 
Justification  
To examine the 
economic impact and 
health outcomes of 
NewbornDx  and 
rWGS in infants 
compared with SOC 
diagnostic testing, 
over a one -year and 
lifetime horizon  Secondary  One-year cost-effectiveness 
of NewbornDx  and rWGS 
compared with SOC testing  Assess economic 
value of 
alternative testing 
strategies  
Secondary  Lifetime cost -effectiveness of 
NewbornDx  and rWGS,  
compared with SOC testing  Assess economic 
value of 
alternative testing 
strategies  
To develop and 
qualitatively assess 
the web-based clinical 
reference database of 
supporting information 
for medical providers 
and parents  Secondary  Satisfaction of the web -
based clinical reference 
database  Assess ease of 
use and 
usefulness of 
information  
among medical 
providers   
Exploratory 
Objectives  Endpoints  Endpoint 
Justification  
To inform the 
NewbornDx  panel 
with findings from 
rWGS that were not 
identified with 
NewbornDx  Exploratory   Conditions detected by 
rWGS that were not detected 
by NewbornDx  Expand and 
improve the 
diagnostic 
accuracy of the 
NewbornDx  panel   
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
33 How endpoint(s) will be adjudicated   
1. Confirmed genetic disorders detected by NewbornDx  or rWGS: the laboratories  
conducting testing could report descrepant  results  due to differences in  
confirmatory methodology , variant types  or methods of interpretation . Methods 
used for confirmation testing at each laboratory will be documented.  If results are 
discordant  due to a variant classification , the laboratories will each provide the 
evidence supporting  their result and  variant classification . This summary  will be 
given to the  enrolling site PI to share with the clinical team ; a subsequent phone 
call with the labs may be arranged upon request from the site . The clinical team 
who is caring for t he infant is in the best position to determine if one result aligns 
best with the infant ’s clinical presentation  and their view will be captured in the 
study data. Additionally, a subset of the study geneticists  on the steering 
committee  who are independent of the labs will review the redacted lab reports 
and lab summaries and provide what they think is the most accurate result for an 
additional study endpoint. The labs are available for questions by the steering 
committee. The opinion of  the steering committee members may be shared with 
the enrolling site upon the site’s request.  Detailed procedures are outlined in the 
MOP.  
2. Clinical utility of genomic sequencing testing : it is possible that the clinician 
completing the clinical utility su rvey (refer to section 8.1) might indicate an 
opinion or action that differs from the medical record data abstraction reported by 
the study coordinator on the Clinical Actions after Genomic Sequencing form.  In 
such a case, the research team at the site wil l review the relevant information 
with the clinical team to find out and document the reason for the discrepancy 
and if applicable, make any corrections (i.e. a survey completed for the wrong 
infant ). 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
34 4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
 
This multicenter, prospective, clinical trial will estimate the diagnostic yield of 
NewbornDx  and rWGS  testing and assess the clinical utility of genomic  sequencing  
among high -risk infants with signs/symptoms consistent with a possible genetic 
disorder . The relative cost effectiveness of each testing method  will be evaluated  
through simulation .   
There are three components to this study:  
1. Infants will undergo SOC diagnostic testing as well as NewbornDx  and rWGS  in 
parallel . Genetic sequences via NewbornDx and rWGS will be generated for the 
infant (proband) and when available, the biological parents, and analyzed  
together . NewbornDx and rWGS test results will be returned to the infant’s 
clinician, medical record and parent/guardian. Those infants analyzed as  a duo 
or trio will have a retrospective analysis done of only the infant’s data to 
determine if the same result would have been obtained with and without parent 
samples. Clinical utility will be measured by clinician opinion and changes in the 
infant’s ca re as a result of the genetic sequencing test results. QoL and medical 
resource utilization will be collected  by parent survey monthly,  until the infant is 
one year CGA .  
2. A retrospective chart review of neonates with suspected genetic disorders 
completed at 3 sites , will be used  to elucidate  1-year cost and health outcomes 
that would have been incurred in the absence of available NewbornDx  and rWGS 
testing.  The retrospective review will include 300 neonates born 12 -18 months 
prior to the start of the study  and performed under a separate ly submitted 
amendment to the central  IRB. The cost and health outcome data will be used in 
an economic e valuation comparing NewbornDx , rWGS, and SOC over 1 -year 
and a child’s lifetime time trajectory.  
3. A user-friendly clinical reference database will be  developed  to provide medical 
providers and families  with information about genetic disorders , treatments, 
clinical trials and advocacy groups . A qualitative assessment of the clinical 
reference database  will be conducted through  surveys  of clinicians involved in 
the infants’ care. Once the database is completed and  prior to implementation of 
the clinical reference database in to this study, an amendment will be submitted to 
the IRB along with the survey.  
 
Hypothesis #1: NewbornDx  will detect at least 60% of the diagnoses identified  by rWGS  
 
Hypothesis #2: NewbornDx  will be substantially less costly than rWGS  or SOC testing 
over a one year and lifetime horizon  
 
Hypothesis #3: Medical providers will be sat isfied with the web-based clinical reference 
database of supporting information.  
 
Interim analyses are  not planned.   
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
35 4.2 SCIENTIFIC R ATIONALE FOR STUDY DESIGN  
 
There is a strong need for prospective, comparative studies comparing the applicability 
of NewbornDx  and rWGS in the neonatal population. While studies have been done 
comparing WES/WGS in the NICU, they lacked generalizability to a larger population 
since: 1) they were underpowered or were not prospective, 2) patients were selected 
based on a positive fa mily history, or 3) the variants were detected in previously 
characterized genes and therefore potentially detectable on the NewbornDx  panel. As 
such, no prospective assessment of the clinical utility, cost - effectiveness , or outcomes 
associated with a NewbornDx -based diagnosis of genetic diseases has been 
conducted. The proposed study design will maintain equipoise with direct comparative 
analysis between two comprehensive genetic sequencing approaches for use in infants  
in an attempt to determine their co st-effectiveness and diagnostic yield for use in this 
vulnerable population.  
 
4.3 END OF STUDY DEFINITION  
 
An infant  is considered to have completed the study if he or she has undergone 
NewbornDx  and rWGS and  completed the last interview at 1 year CGA or died prior to1 
year CGA .  
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
36 5 STUDY POPULATION  
 
5.1 INCLUSION CRITERIA  
 
In order to be eligible to participate in this study, an infant must meet all of the following 
criteria:  
1. Documented informed consent from the parent/guardian   
2. Signs/symptoms consistent with a possible genetic disorder including, but not 
limited to dysmorphic features, congenital anomalies, hypotonia, seizures, 
clotting, poor oral feeding skills  
3. Admitted to a hospital (NICU, PICU, CVICU , inpatient floor ) participating in this 
study  at the time o f enrollment  (enrollment is not limited to the initial 
hospitalization after birth, it may occur during a readmission)   
4. Less than one year CGA   
 
There is not a requirement for clinical genetic testing prior to enrollment. However, 
enrollment in this study  is not intended to replace targeted available genetic testing for 
specific  suspected disorders that match the phenotype of the infant  and make rWGS 
testing unnecessary. Examples include trisomies or a high likelihood of DiGeorge 
syndrome. In these cases, targeted genetic testing for a suspected disorder should be 
done prior to enrollment ( e.g. DiGeorge syndrome and FISH for 22q11.2 deletion).  
Clinical genetic testing does not need to be completed prior to enrollment if there is 
more than one diagnosis on t he dif ferential diagnosis list.  Other than these few 
situations , our goal should be to understand the role of utilizing rWGS and NewbornDx 
as a first line choice of testing.  
 
5.2 EXCLUSION CRITERIA  
 
An individual who meets any of the following criteria will be  excluded from participation 
in this study:  
1. A known genetic  diagnosis (e.g. prenatal testing , biochemical testing and/or 
enzyme analysis )  
2. Major congenital anomaly (renal, cardiac, hepatic, neurologic, or pulmonary 
malformations) associated with a chromosomal anomaly detected on prenatal 
testing (e.g. ultrasound, genetic testing)  
3. Presence of documented congenital infection (e.g. congenital cytomegalovirus)  
4. Infants considered non -viable due to prematurity (< 23 0/7 weeks GA)  
5. Infants who are not expec ted to receive medical care in the US healthcare 
system from time of  discharge home until 1 year CGA  
 
Lack of participation by one or both biological parent s in the trio analysis does not 
preclude the infant from participating in this study. This situation could occur if a 
biological parent  does not provide consent for his/her own blood sample to be used for 
a trio analysis,  if a blood sample cannot be obtained , or in the case of a n egg or  sperm 
donor . 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
37 5.3 SCREEN FAILURES  
 
Screen failures are defined a s infant s who se parent(s)  consent to participat ion in the 
clinical trial but who do not have NewbornDx  or rWGS  performed . This could occur if a 
clinical diagnosis was determined after consent was obtained but prior to the start of 
any study procedures  (section 7 addresses the procedure for subject withdrawal if a 
clinical diagnosis is determined after study procedures  commence  but before the 
completion of genomic sequencing) . A minimal set of screen failure information will be 
collected  including demography, screen failure details  and eligibility criteria.   
 
5.4 STRATEGIES FOR RECRU ITMENT AND RETENTION  
 
The an ticipated number of infants to be  screened is  approximately  1200 in order for 400 
infants to complete the study. Six  US sites will recruit for this study.  The 
parent/guardian (s) of all eligible infants will be approached.  Enrollment is expected to 
include about 50% of each sex and proportions of each race that are represented in the 
general population in the multiple sites where the studies will be performed. The entire 
ICF will be translated into Spanish and short forms in other non -English languages will 
be utilized.  
 
This study involves monthly follow -up from discharge home until 1 year CGA . In order to 
reduce the risk of lost to follow -up, study staff will have the parent/guardian (s) fill out the 
Follow -up Contact Information form at the time of transfer or discharge home. Th is form 
will document several methods of contact for the parent/gu ardian (s) and a family 
member or friend who would know how to reach the parent/guardian (s) if their contact 
information change s or they are unreachable. Then, the study coordinators will contact 
the family monthly until 1 year CGA  to complete the parent surveys/ interviews.  
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
38 6 STUDY INTERVENTION  
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION  DESCRIPTION  
 
NewbornDx  and rWGS are CLIA/CAP certified  and will be completed  for all infants. The 
Athena (Quest)  and RCIGM laboratories will be blinded to each other’s result  until all 
final results are returned.  
 
Phenotype Extraction  and Provision of Clinical Information to the Laboratories  
1. A sub -group of clinicians from each site  will manually review the  medical record , 
extract relevant clinical information  and determine the  Human Phenotype 
Ontology  (HPO ) terms  (refer to MOP) . The sub-group  of clinicians  will consist of 
a minimum of 3 clinicians with at least one a geneticist or genetic counselor.    
2. A small portion of the medical record s (genetics  consult note, other sub -specialty 
note (neurology, hematology, etc.) and NICU note s will be selected.  
3. The HPO terms and medical records  will be provided by the sites to the 
laboratories via upload to the  RCIGM ordering portal. Athena  will receive  this 
data to its systems through a secure  FTP site  or encrypted email . Athena  will not 
have access to the rWGS results  through this mechanism . 
4. Once  HPO terms are submitted by the site, the laboratories may either add 
additional terms based on the last consult/p rogress notes submitted by the site or 
contact the site research team for clarification of symptoms. If this happens by 
either Athena (Quest)  or RCIGM, the additional or revised HPO terms  needs to 
be redirected to the site for upload to the portal . This ensures any new 
information is shared with both laboratories.    
 
Athena Diagnostics  (Quest)  
NewbornDx  Methods  and Workflow  
Rapid NewbornDx  will be performed at Athena (Quest)  Diagnostics to CLIA/CAP 
requirements. DBS will be collected on filter paper and sequenced. Custom 
oligonucleotide probe libraries (Agilent SureSelectQXT) will be utilized to capture 
genomic DNA regions and targeted libraries created as described earlier42. The content 
of the assay (regions of interest) will remain constant for participants in the study. 
Sequencing of the targeted libraries will be performed on a NextSeq 500 (Illumina, San 
Diego, CA). Sequencing reads will be aligned to the reference genome  (hg19/GRCH 
build 37) using Burrows -Wheeler Aligner for short alignments (BWA -MEM) followed by a 
Genome Analysis Toolkit v3.6 (GATK) haplotype variant caller running on the Edico 
Dragen™ Platform, and annotated with Enterprise genome interpretation softwar e 
(Fabric Genomics, Oakland, CA). All subject FASTQ, Variant Call File ( VCF) and other 
data files will be securely stored within the Athena (Quest)  Diagnostics Isilon storage.  
 
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
39 Athena (Quest)  Genomic Data Analysis  
Data analysis will be completed by a custom bioinformatics pipeline utilizing Burrows -
Wheeler Aligner & Genome Analysis Toolkit v3.6. All reported DNA variants will be 
reviewed by at least one trained genomic variant scientist, one genomic science 
specialist , and one board -certified laborator y director prior to the final report being 
issued.  
 
Athena (Quest)  Variant Pathogenicity Determination   
Variant pathogenicity is assessed following a standardized evaluation protocol71 
consistent with the ACMG standards and guidelines for the interpretati on of sequence 
variants49. Data is gathered from multiple sources, including but not limited to, internal 
datasets, published literature, public databases, and in -silico prediction tools. Evidence 
is reviewed and assessed by a genomic variant scientist usi ng a standard operation 
procedure . The proposed pathogenicity classifications derived from the data are 
reviewed and approved by a board -certified laboratory director.   
 
Athena (Quest)  Variant Causality Determination  
Variant causality will be determined by the infant's clinical presentation, family history, 
and any other laboratory results provided. Relevant HPO terms (see phenotype 
extraction above) will be used with Phenomizer or Phenolyzer to create a differential 
diagnosis based on the neonate’s clinical presentation. Phevor  (Fabric Genomics ) will 
be used to prioritize DNA variants based on the genes’ associated phenotypes 
compared to the HPO terms provided by the site . Fabric Genomics will also be used to 
filter variants based on variables such a s inheritance pattern, frequency of the DNA 
variant in the general population, variant type (missense, nonsense, etc.), and presence 
in a variant database  (i.e. ClinVar or HGMD ). Variant filtering will be based on a 
standardized set of criteria used by  genomic variant scientists and board -certified 
laboratory directors. Sample reports will be drafted and reviewed by a team composed 
of genomic variant scientists, genetic counselors, and a board -certified director prior to 
being released to the client.  
 
RCIGM -CGC   
rWGS Methods and Workflow  
rWGS will be performed at the CLIA -certified, CAP accredited Rady Children’s Institute 
for Genomic Medicine – Clinical Genome Center (RCIGM -CGC). Sequencing is 
performed in accordance with the RCIGM - CGC standard operating procedures and 
validations. Brief ly, genomic DNA is extracted from whole blood, PCR -free DNA libraries 
are made, and quality checks performed for library size and concentration. DNA 
libraries are then loaded on a NovaSeq 6000, and 2 x 100 nt sequencing to an average 
genome wide coverage o f 40x. Short Tandem Repeat (STR) genotypes will be used to 
assure sample identity is maintained throughout the laboratory process. For each infant  
or biological parent  sample, STR genotypes are generated by a commercial PCR 
amplification kit and are compar ed with those called by WGS process. Bcl files are 
automatically aligned to hg19/GRCH build 37 and nucleotide variants and small 
insertions and deletions are called with DRAGEN (Edico Genome) in ~1 hour. Files are 
uploaded to DNAnexus, where structural var iants (SVs) are called using  the union of 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
40 two algorithms ( CNVnator  and Manta). Redundant SVs are removed from the superset 
of SV calls. SVs will be annotated to determine affected genes and regulatory regions 
and compared to public and internal databases t o determine MAF and filter common, or 
false positive SVs. A combined VCF (SNVs/indels and SVs) are uploaded to a rapid 
instance of Opal (Fabric Genomics), allowing annotation and display within 1 hour.  
 
rWGS Trio Testing  
When samples for the infant and pa rent(s) are received at the same time, RCIGM will 
generate infant and parent sequences simultaneously  and the data from the infant and 
parent(s)  will be  analyzed together  as a duo/trio . When infant samples are sent without 
the parent samples, RCIGM will sequence the infant sample and analyze the infant’s 
data. If a diagnosis is not determined or a VUS is identified after analyzing the infant 
alone, the parents’ samples, if subsequently become available, will be sequenced and 
data from the duo or trio anal yzed together. The infant’s report of results will indicate 
whether or not trio testing was done.  For all positive diagnos es made when  only 
sequenci ng and analyzing the infant, the lab will subsequently  run testing on the parent 
samples  (if available ) to determine inheritance (for example, targeted Sanger 
sequencing ). 
 
RCIGM -CGC Genomic Data Analysis  
Data analysis will follow the standards set by the clinical diagnostic laboratory and in 
accordance with recommendations from the American College of Medi cal Genetics and 
Genomics (ACMG/AMP). A minimum of two expert data analysts will be responsible for 
analyzing the DNA variants following genomic sequencing. Analysts will be rotated 
among qualified staff, including but not limited to laboratory directors, genetic 
counseling staff, and trained medical and research staff. One of the analysts will then 
compile a report to be reviewed and reported by a n ABMGG board -certified laboratory 
director . 
 
RCIGM -CGC Variant Pathogenicity Determination   
The laboratory directors as well as Medical Geneticists and Genetic Counselors at 
RCIGM and at each site will assess pathogenicity of variants according to ACMG/AMP 
recommendations for classifying sequence . New statistical approaches for variant 
classifica tion are currently being actively developed by several groups and may be 
introduced upon verification of their utility. Knowledge of the pathogenicity of individual 
SNVs and SVs is rapidly evolving through community curation via HGMD, ClinVar and 
DECIPHER5 0 and through exhaustive mutant generation and functional testing for 
individual disorder genes. Variant classification will be performed using expert analysis 
of all data regarding each variant, including review of available literature and functional 
mode ls.  
 
RCIGM -CGC Variant Causality Determination:  
Variant causality will be determined on a case by case basis depending on the infant's 
clinical presentation, family history, and any other laboratory results provided. Relevant 
HPO terms will be used with software tools, such as Phenomizer or Phenolyzer  or 
standard gene lists for common presentations (e.g. neonatal seizures, cholestasis, and 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
41 heterotaxy), to create a differential diagnosis list based on the neonate’s clinical 
presentation. Inputs for causali ty determination will be the annotated genomic variant 
file and the comprehensive differential diagnosis gene list. Alternatively, the Phevor tool 
in Opal52, 53 will be used to rank genes with relationship to the observed phenotype 
based on their known or suspected association(s). By allowing dynamic filtering of 
variants based on variables such as individual clinical features, disorders, genes, 
genotype, and inheritance pattern, Opal will assist in identification of a molecular 
differential diagnosis. Cust om Opal settings can be saved, which allows configuration in 
a manner that can enable a provisional diagnosis to be determined rapidly. Opal also 
allows data mark -up, user tracking and data basing of variants and their classifications 
and export of fields in formats suitable for inclusion in diagnostic reports. In a typical 
interpretation session, variants will be filtered by allele frequency and presence in 
variant databases and prioritized based on phase, parent -of-origin, clinical features, and 
other cha racteristics unique to the infant  or to the biological parents . All potential genetic 
inheritance patterns will be examined, including de novo, autosomal recessive, 
autosomal dominant, X -linked, mitochondrial, and, where possible, somatic variation 
(where trios may be needed). Where a single likely causative heterozygous variant for a 
recessive disorder is identified, the entire coding domain will be manually inspected 
using the Integrated Genome Viewer (IGV) for coverage and to screen for additional 
varian ts that may not have been called. Expert interpretation will be performed for all 
likely causative variants with regard to evidence for pathogenicity and causality. 
Likewise, the causality of structural variants in rWGS is assessed based on frequency in 
the RCIGM -CGC database and location with respect to the comprehensive differential 
diagnosis gene list54. This is an evolving area of interpretation . SV and nucleotide 
variant causality is examined together in order to identify compound heterozygosity in 
recessive disorders.  
 
Secondary /Incidental  Findings  for the Infant  
Secondary /incidental  findings for an infant will not be actively sought. A dedicated 
analysis of the ACMG 59 secondary gene list will not be done. If a secondary /incidental  
finding is found during the infant analysis, t he laboratory will only report it if both criteria 
1 and 2 are met and either 3a or 3b:  
1. The parent/guardian opted to receive secondary findings for the infant, AND  
2. The disorder onset may occur in childhood, A ND 
3. At least one of the following:  
a) The disorder is medically actionable AND/OR  
b) The disorder involves a gene on the “American College of Medical Genetics 
and Genomics (ACMG) list” of genes recommended for reporting of 
secondary findings at the time of testi ng 
 
Secondary findings of conditions with an onset only in adulthood will not be returned  for 
the infant . Only pathogenic  or likely pathogenic  variants are reported as a secondary/  
incidental finding  if they have the potential to impact the infant during childhood . 
 
The “ACMG list ” refers to the current list of genes recommended to report as secondary 
findings. WGS covers all 59 genes  currently  recommended by the ACMG to return as 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
42 secondary findings, NewbornDx  covers 30 of those genes. There are 52 genes on the 
ACMG list that may occur in childhood. In order to account for how the ACMG list might 
evolve during the study period, the ACMG list at the time testing is done will be used. 
Therefore, the list used for the first infant enrolled  may be differ ent than the list used for 
the last infant enrolled.  If the ACMG list evolves during the study period, we will not 
retrospectively change what was initially reported; this aligns with current clinical 
practice.  
 
Primary  and secondary  findings for the infant, if reportable, will be included in one report 
from each laboratory.  
 
Secondary Findings for a Biological Parent  
A secondary finding for a biological parent may be identified through WGS  when 
conducting the infant’s phenotypically driven analysis . Secondary findings for a parent 
will not be actively sought  and a  dedicated analysis of the ACMG 59 secondary gene list 
will not be done. There may be cases in which a biological parent elects to receive 
secondary findings  and the parent’s sample does not undergo WGS . This could occur if 
the infant’s samples have been processed prior to the receipt of the parent samples. 
Secondary findings for a biological parent will not be reported by Athena  Diagnostics .  
 
The laboratory will only report a secondary diagnosis for a biological parent if all of the 
following criteria are met:  
1. The biological parent opted in to receive secondary findings for him or herself . A 
parent may opt -in to receive secondary findings  only if the parent/guardian opted -
in for infant secondary findings.  
2. The disorder is of a gene on the ACMG list of genes recommended to report as 
secondary findings at the time of testing .  
 
A separate report must be issued for any secondary findings for a biol ogical parent.   
 
When Incidental/Secondary Findings Are Reported  
Secondary/I ncidental finding found in Infant and 
Parent  Did Infant 
Opt-In? Report  for 
Infant?  Did 
Parent 
Opt-in? Report  for 
Parent?  
Included in ACMG59, adult onset  Yes No Yes Yes, RCIGM*  
Included in ACMG59, adult onset  Yes No No No 
Included in ACMG59, adult onset  No No No No 
Included in ACMG59, childhood onset  Yes Yes Yes Yes, RCIGM*  
Included in ACMG59, childhood onset  Yes Yes No No 
Included in ACMG59, childhood onset  No No No No 
Not on ACMG59, childhood onset, medically actionable  Yes Yes Yes No 
Not on ACMG59, childhood onset, medically actionable  Yes Yes No No 
Not on ACMG59, childhood onset, medically actionable  No No No No 
*Athena/Quest will not report secondary/incidental  findings for parents.  
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
43 Confirmatory Testing  
With the exception of a provisional result, pathogenic and likely pathogenic variants (as 
determined by ACMG variant classification criteria) that relate to the neonate’s current 
phenotype as well as suspicious VUS will be clinically confirmed at RCIGM or Athena  
prior to the return of written results. Additional confirmation testing may be done by 
Sema4 for subjects enrolled at Mount Sinai (refer to Sema4 section below). Segregation 
analysis  on biological parent s will be performed when warranted. A provisional result 
will be given i n cases in which delaying the return of results until confirmatory testing 
occurs places the infant  at an increased risk of morbidity or mortality (a treatment 
modality is available whose delay in administration could cause irreversible harm ). Prior 
to confirmation testing, the laboratory will return provisional results and  management 
guidance via verba l report with  read back followed by a written provisional result report 
to the enrolling site . Refer to the section, Sema4 and Subjects Enrolled at Mount Sinai, 
for when provisional results may be given for subjects from Mount Sinai.   
 
Confirmatory testin g will subsequently be performed for all provisional results and a 
written report of the final result issued.  The laboratory will make the decision about 
whether a finding meets the criteria to be given provisionally; if there is a question, the 
lab will c onsult with the study -wide PIs. A lethal condition will not be released as a 
provisional result; it will be confirmed prior to this result reported.  
 
Variant Classification  Is confirmation testing needed?  
Pathogenic  Yes 
Likely Pathogenic  Yes 
Variant of Unknown 
Significance (VUS)  Only if suspicious  (where the phenotypic fit is very good 
and/or functional confirmatory tests are readily available 
and/or the results are actionable )  
Likely Benign  No 
Benign  No 
 
Secondary diagnoses  Is confirmation 
testing needed?  
A secondary  or incidental  finding  that will be reported  Yes 
 
Category  Definition  Detected  
By NewbornDx  Detected  
by rWGS  Method(s)  
SNP variation in a single 
nucleotide  Yes Yes Confirmation 
testing methods 
are at the 
discreti on of the 
laboratory director. 
Common methods 
include MLPA , 
microarray , 
Sanger and qPCR.  Indel  an insertion or 
deletion of less than 
1 kb in length, in -
frame and frame shift  Yes Yes 
Structural 
Variant  Inversions, balanced 
translocations, 
CNVs; ~ 1 kb and 
larger  No Yes 
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
44 Sema4 and Subjects Enrolled at Mount Sinai  
Results returned to the medical record for subjects from Mount Sinai must be from a 
New York State CLIA certified lab and of a New York State conditionally approved test. 
Athena Diagnostics is a New York State CLIA certified lab and NewbornDx is a New 
York State conditionally approved test. Therefore, NewbornDx results for subjects from 
Mount Sinai will be returned to the research team, clinician(s) caring for the subject, the 
subject’s parent/guardian(s) and placed in the subjects’ medical record. Provisional 
results from NewbornDx may be acted upon prior to Athena’s own confirmation testing.  
 
Until the time RCIGM becomes a New York State CLIA certified laboratory and rWGS a 
New Y ork State conditionally approved or approved test, s ubjects from Mount Sinai may 
require additional confirmation testing by Sema4 . Sema4 is a New York State CLIA 
certified and Mount Sinai wholly owned laboratory . Procedures to be  followed:  
1. The research tea m at Mount Sinai will send samples to Sema4. Sema4  will 
extract DNA from the infant and biological parent blood samples and send two 
aliquots to RCIGM -CGC while retaining an aliquot for possible future confirmation 
testing. DNA requirements: > 3 ug DNA (co ncentration ranges from 20 ng/ul to 
200 ng/ul) with Picogreen measurement. If the site used non -Picogreen 
measurement, 4 -5 ug DNA (concentration ranges from 20 -200 ng/ul).  
2. RCIGM will issue  a research grade report of its results to the research team at 
Moun t Sinai. This report  will have the heading “research report” and also include  
disclaimers  in the Regulatory Disclosures section. The research report will only 
be placed in the research file and not in the medical record.  
3. A provisional result will be given to the research team in order for them to alert 
Sema4 to start confirmation testing if required (i.e. RCIGM reports a provisional 
result which is not also reported by Athena). A RCIGM provisional result will not 
be shared  with the clinical team, parent/guardian nor put in the medical record.  
4. Pathogenic, likely pathogenic or VUS results returned only by RCIGM  will have 
additional confirmation testing and interpretation done at the Sema4 laboratory. If 
RCIGM and Athena repor t the same result, Sema4 confirmation testing is not 
required.  At Sema4, confirmation testing will be done by targeted analysis with 
Sanger, or for CNVs with qPCR, MLPA, or ultra -high resolution exon array.  
5. RCIGM will send final results as a research report to the Mount Sinai research 
team. The  Mount Sinai research team will compare the RCIGM research report 
with Athena’s report  and alert Sema4 of confirmation testing as necessary .  
 
RCIGM Result  Agreement with NewbornDx  Is testing 
by Sema4 
required?  What reports 
are put in the 
medical 
record?  
Pathogenic, likely 
pathogenic, VUS 
or secondary/  
incidental result  The findings reported by RCIGM are 
also reported  and interpreted  within the 
similar variant classification categories 
(P/LP v. VUS) by Quest/Athena . No NewbornDx  
RCIGM reports findings that Quest/  
Athena did not report.  Yes NewbornDx ,  
Sema4  
Negative Result  Yes No NewbornDx  
No No NewbornDx  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
45 If during the course  of this study,  the RCIGM rWGS test becomes CLIA certified in New 
York State  and the rWGS test is N ew York  State approved  or conditionally approved , 
the processes involving Sema4 will be eliminated . 
 
Discordant Results   
It is possible that the final results of NewbornDx  and rWGS may be discordant. It is also 
possible that the confirmatory testing done by Sema4 for infants enrolled at Mount Sinai  
will be discordant  to the  confirmed  NewbornDx  or rWGS results . This could be a result 
of both technical and  interpretation differences:  
 technical differences of the platforms where a specific variant may be identified 
on one platform but not another  
 different genotyping and variant filter thresholds when both platforms return the 
same variant  
 different classif ication of the same variant as benign, likely benign, VUS, likely 
pathogenic or pathogenic  
Which methods are used for confirmation testing at each laboratory will be documented .  
 
It will be determined if the discordance is caused by the technical  performance of the 
platform  or variant filtering or classification . In cases of discordance due to variant 
classification, each lab will use an agreed upon format to provide a written document 
summarizing  the evidence supporting their variant classificati on. Refer to section 8.1 
and the MOP for adjudication procedures.  
 
Inconclusive Results  
Under certain circumstances, a test result may not be conclusive. These situations will 
be reviewed on an individual basis and testing may be repeated or another sample  
requested. The reasons for inconclusive testing are explained in the result report.  
 
Requests for Re-analysis of Sequencing Data  
Requests for reanalysis can only be made after  a significant change in phenotype 
occurs  in the infant  (e.g. new onset seizures ) when  results have already been returned . 
This may be permitted on a case -by-case basis only after discussion  between the 
enrolling site PI and study -wide PIs . 
 
Retrospective Singleton (Proband)  Analyses  for Duo/Trios  
After the final result is returned for an infant using a duo or trio analysis, Athena  
analysts will conduct a  retrospective  analysis of only the infant’s NewbornDx data . The 
purpose of this analysis is  to determine if  the same result  obtained with a duo/trio could 
have been obtained with only the infant’s sample.  The analysts who conduct the 
retrospective analysis will not know the result that was returned for the subject. The  
retrospective infant -only analyses will occur on a periodic  basis throughout the study.  
 
RCIGM  will also perform a retrospective infant -only analysis on all subjects utilizing 
either an Artificial Intelligence platform or by performing a manual analysis similar to 
Athena  at the end of the study . 
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
46 6.2 STUDY INTERVENTION  COMPLIANCE  
 
Adherence to the protocol regarding the study intervention will be assessed through the 
monitoring of critical processes as detailed in the Data and Safety Monitoring Plan 
(DSMP).  
 Site procedure for maintaining accurate link of infa nt with study ID number  
 Site procedure to ensure correct labeling of blood/DNA sample(s)  
 Accurate and relevant Human Phenotype Ontology terms and clinical information 
submitted by the enrolling site to the laboratory for use in analysis of variants with 
phenotype  
 Laboratory protocols adhering to CLIA /CAP/state  guidelines  
 Laboratory procedures for accurate matching of a result with the infant  
 Laboratory procedures to ensure any secondary findings for the infant  are only 
reported  if the criteria pertaining  to the infant as outlined in section 6.1.1 are met  
 Laboratory procedures to ensure secondary findings  for a biological parent  are only 
reported if the criteria pertaining to a parent as outlined in section 6.1.1 are met  
 Confirmation testing completed prior to reporting of pathogenic, likely pathogenic , or 
suspicious VUS results or the documentation of a provisional result exception  
 Accurate dissemination of the report of results from the laboratories to the infant ’s 
EMR  
 
6.3 CONCOMITANT THERAPY  
  
There are no restrictions on concomitant medications, treatments or procedures allowed 
during the study. Medications and  procedures will be captured during data  collection.  
 
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
47 7 STUDY INTERVENTION  DISCONTINUATION  AND PARTICIPANT  
DISCONTINUATION / WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTIO N 
 
The study intervention is  diagnostic test s. Discontinuation of the study intervention 
might occur if a clinical diagnosis is determined prior to the completion of NewbornDx  or 
rWGS . In this case, the infant  will be withdrawn from the study per section 7.2.  
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
 
An infant’s  parent/guardian  or a biological parent can withdraw their own participation at 
any time and is not obligated to  state the reason for withdrawal.  However, the 
investigator should make a reasonable effort to ascertain the reason for withdrawal 
while fully respecting the parent/guardian’s  or biological parents’  rights.  
 
An investigator may discontinue or withdraw a n infant  from the study for the following 
reasons : 
 A clinical diagnosis was determined prior to completing the genomic testing for 
the infant   
 Withdrawal is requested by the NIH or DSMB  
 If the infant  meets an exclusion criterion (either newly developed or n ot 
previously recognized) that precludes further study participation  (i.e. CMV testing 
that came back positive after enrollment)  
 If the blood samples cannot be safely obtained from the infant  
 The parent/guardian  withdraws consent for the infant  
 
The reason for discontinuation of the infant  or biological parent will be recorded in the 
study database . An infant for whom the parent/guardian provided consent but who does  
not receive the study intervention may be replaced. An infant for whom the 
parent /guardian provided consent and who  receive d the study intervention  and was 
subsequently withdraw n from the study  will not be replaced . 
 
In the event of an infant  death prior to the completion of genetic testing, the testing will 
continue to be done unless the parent/guardian indicate s otherwise. There is a potential 
to provide information regarding a hereditary disorder for future children.  
 
If an infant  is withdrawn  from the study, the data already collected on the infant  may be 
used unless the parent /guardian  indicates otherwise in writing .   
 
The following actions will be taken at the local study site and laboratories as applicable  
after receiving a reques t to withdraw : 
 Upon receipt of request to withdraw, the enrolling site  will notify RCIGM  and 
Athena (Quest)  of withdrawal of the infant and/or the biological parent(s) . Mount 
Sinai will also notify Sema4.   
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
48  The enrolling site or laboratories that are in possession of unused blood from the 
infant  and/or the biological parent (s) will ensure blood samples are  destroyed.  
 Isolated DNA will be destroyed. The laboratories will p ermanently break any link 
between personal identifying information and sequencing data  files from the 
infant  and/or the biological parent (s).   
 The RCIGM laboratory will remove the  REDCap  Infant Study ID from its ordering 
portal.  
 If a back -up of the invent ory database/informatics system is ever restored, then 
the laboratory should ensure that the relevant identifying records stored on the 
discarded samples log are again deleted from the records.  
 The enrolling site must document reasons for withdrawal  and record it in the 
REDCap  database . 
 The enrolling site will permanently break any link between personal identifying 
information and the anonymized records  and data  in REDCap  by replacing 
protected health information (PHI) in the Master List of enrolled subject and 
REDCap  Study  Infant  ID with a note that the infant  has withdrawn.  
 The enrolling site and laboratories must shred any hard copies of associated 
identifying information not required to be maintained for regulatory purposes.  
 The enrolling site must retain the executed consent form and request for 
withdrawal in a separate, secure file of discontinued infant s and redact any 
identifiers that link the infant  to the data (such as infant ’s study ID number).  
 The laboratories will cer tify that identifying links have been broken  and as 
applicable, that biological material has been destroyed.  
 Only anonymous data may be used for future research after consent has been 
revoked.  
7.3 LOST TO FOLLOW -UP 
 
An infant  will be considered lost to follow -up if the enrolling site  is unable to contact a 
parent /guardian  at the time the infant turns 1 year CGA  plus 2 month s. In order to 
reduce the risk of lost to follow -up, study staff will have the parent /guardian (s) provide  
several methods of contact for themselves  as well as a family member or friend who 
would know how to reach them if their contact information changed or are unreachable  
(refer to Follow -up Contact Information form) . The enrolling site  will attempt to contact 
the parent /guardian (s) monthly. Before an infant  is deemed lost to follow -up, the 
enrolling site will make every effort to regain contact with the infant  (multiple  contacts  
and, if necessary, a certified letter to the infant ’s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the infant ’s 
study file. If the infant  continues  to be unreachable, he or she will be considered to have 
withdrawn from the study with a primary reas on of lost to follow -up. It is p ermissible  to 
contact the infant ’s primary care provider to obtain relevant information on the condition 
of the infant if the parent/guardian(s) are not available  and they have given permission 
by signing the ICF and/or medical record release form . 
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
49 8 STUDY ASSESSMENTS AN D PROCEDURES  
 
8.1 SCREENING & INFORMED  CONSENT  
 
Screening  
Infants born with a suspected genetic disorder will be screened for all inclusion/  
exclusion criteria. Potential infant s will be identified  by study personnel reviewing the 
daily census  of applicable hospital locations  and relevant  medical record s or by the 
clinical team . Study or clinical personnel will identify potential candidates based on the 
primary diagnosis, signs/ symptoms , and CGA . The study team will discuss eligibility of 
the infant with the attending physician of record  and if  in agreement, the family will be 
approached for the study.  
 
There is not a limit to how many infant s can be enrolled at any one site. Infant s who are 
alrea dy an inpatient at the time a site opens for enrollment may be approached for this 
study if they fulfill the inclusion /exclusion criteria.  Those infants identified through the 
screening process will have the following data recorded on the Screening Log  and/or 
entered into REDCap  The Infant S tudy ID will be used to code screening data  and is 
generated by REDCap  consisting  of a 4-digit number ( 1-digit site number and a 3-digit 
infant number ). 
 
Category  Information from the medical 
record which may be recorded  
on a paper or electronic 
screening log kept securely at 
the enrolling site  Screening data that will be 
entered into REDCap if the 
infant is approached for study 
participation regardless of 
consent status  
Identifying 
Information  name, date of birth, medical 
record number  N/A 
Screening 
Process  screening ID, date screened, 
location in hospital, whether or 
not the infant is eligible, if the 
family was approached for 
consent, date of approach, 
reason why an eligible infant was 
not approached  screening ID   
Clinical 
Information  gestational age at birth, age at 
time of screening, clinical 
signs/symptoms  and primary 
system involvement , clinical 
differential diagnosis, prenatal 
and postnatal clinical genetic 
testing and newborn screening 
results, list of gene tic tests gestational age at b irth, age at 
time of screening, primary 
system(s) involvement related to 
patient nomination, sex of infant  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
50 pending, newborn screening test 
results, sex of infant  
Consent 
Process  languages used during the 
consent process; if telephone 
consent was used; if clinical 
genetics was involved prior to the 
consent process; enrollment 
status; reason for declining study 
if voluntarily given  languages used during the 
consent process; if telephone 
consent was used; if clinical 
genetics wa s involved prior to the 
consent process; enrollment 
status; reason for declining study 
if voluntarily given  
Demographics  type of health insurance, race 
and ethnicity of the biological 
mother and biological father (in 
order to represent the infant)  type of health insurance, race 
and ethnicity of the biological 
mother and biological father , 5-
digit zip code   
 
Identifying information from the screening log will be destroyed at the end of the study .  
Note: for screened patients that have already been entered into REDCap  under the 
current HIPAA authorization waiver by the IRB , we will first delete the primary 
signs/ symptoms already captured in the database and then add the primary system 
involvement and zip code. The purpose of removing primary signs/ symptoms and 
replacing it with system involvement is to reduce the risk of identification due to unique 
features once zip code is added.  
 
Informed Consent  
Consent by one parent/guardian  is required for participation  by the infant . Each 
biological parent will  give permission to obtain and use his or her own blood sample  and 
elect parental secondary findings . Written documentation of i nformed consent from the 
parent/guardian and/or biological parent(s) must be documented  prior to the conduct of 
any study proced ures. Refer to section 10.1.1 Process of Informed Consent.  
 
If the parent /guardian provides  consent for the  infant to participate , study personnel at 
the enrolling site will: 
 Review the ICF and ensure that it is properly completed   
 Review  whether or not the parent /guardian  opted -in to receive secondary findings  for 
the infant   
 Review  whether or not the biological parent(s) opted -in to receive secondary findings 
for themselves  
 Provide the parent /guardian and  the biological parents , as applicable,  with a copy of 
the signed ICF  
 Notify the attending physician of record of the parent/guardian’s decision to 
participate  
 Record that consent was obtained in the infant ’s medical record  
 Place a copy of the  signed  ICF into the infant ’s medical record  
 File the original signed ICF in the research file  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
51  Complete screening log and  the Demographics, Symptoms and Consent eCRFs in 
REDCap  
 
If the parent /guardian refuses  participation for the infant , study personnel will : 
 Communicate refusal to relevant study or clinical personnel  
 Complete screening log  and the Demographics, Symptoms and Consent eCRFs  
in REDCap   
 
8.2 ENROLLMENT   
 
PI Assessment of whether or not an infant  requires urgent testing  
This protocol will prioritize testing of infants who are severely ill. Infants with the 
following conditions may qualify for the most rapid testing possible:  
 Infant  requires mechanical ventilation  
 Infant  is exhibiting severe neurological complications (i.e. uncontrolled seizures)  
 Infant  is hemodynamically unstable  
 Site PI selects this option at his/her discretion  
There is not a specific timeframe in which urgent testing must be returned; rather, the 
labor atory does its best to expedite testing. Refer to the “MOP  about how to notify 
laboratories of  urgent testing.  
 
Enrollment in REDCap  System  
Complete the enrollment and urgent testing eCRFs  in REDCap . The Infant Study ID  and 
linking infant identifiers will be added to the secure site master enrollment log . The 
Infant Study ID will be used for all data entered into  REDCap  and in study files.  
 
Order ing of  Laboratory Tests, Collect ion and Shipment of Blood Samples  
Three laboratories  are involved in this protocol: Athena (Quest) , RCIGM and Sema4.  
1. Athena  Diagnostics ( a subsidiary  of Quest Diagnostics ) is perform ing the 
NewbornDx  panel (infant and  when available, the  biological parents)  and 
confirmation testing for pathogenic, likely pathogenic  and suspicious VUS 
findings . 
2. RCIGM is performing  rWGS (infant  and when available, the biological parents)  
and confirmation testing for pathogenic, likely pathogenic  and suspicious VUS . 
3. In some circumstances, Sema4 will be  involved with DNA extraction and 
confirmation testing  only for infants enrolled at  Mount  Sinai (refer to section 
6.1.1) .  
 
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
52 Blood Sample Collection   
Blood samples are collected as follows:  
Who  Samples to Collect  
Infant   A minimum of two and maximum of five fully saturated dried blood 
spots  (DBS)  using  study -provided  Perkin Elmer 226 filter paper *  
 Two 0.5ml blood samples in study -provided EDTA tubes  (one 0.5ml  
sample  is acceptable , but two are preferred)  
Mother   Two 0.5ml blood samples  in study -provided EDTA tubes  (one 0.5ml 
sample is acceptable, but two are preferred)  
 One 2mL blood sample  in a study -provided EDTA tube   
Father   Two 0.5ml blood samples in study -provided EDTA tubes  (one 0.5ml 
sample is acceptable, but two are preferred)  
 One 2mL blood sample in a study -provided EDTA tube  
*In circumstances in which an infant meets urgent criteria and where allowing the required 3 -hour 
timeframe for a blood spot card to dry prior to shipping may adversely affect time to diagnosis and 
potential life -saving treatmen t, 1ml of whole blood in an EDTA tube may be obtained in lieu of the blood 
spot card and sent to Athena.  
 
Refer to the MOP for detailed instructions about the timing and source of blood 
samples, collection procedures and documentation of the date/time of blood collection.  
If possible, c ollect blood from the infant at the time of routine clinical testing to minimize 
discomfort. If the clinical team does not feel it is safe to withdraw 1ml of blood from the 
infant , wait until just prior to the time a packed red blood cell transfusion is administered . 
 
All blood samples will be obtained by qualified staff following the hospital guidelines and 
standard precautions.  DNA extracted and held prior to enrollment may be used for this 
study (i.e. the clinical team obtained a sample prior to putting an infant on ECMO 
knowing an untainted sample may be needed later for clinical purposes).  
 
Obtain whole  blood samples from each biological parent near the time the samples are 
being collected from the infant . In the case of an assay failure or a damaged sample, an 
additional blood sample  for the infant or a biological parent  may be obtained and 
shipped to the laboratory.   
 
Labeling of Blood Samples  
Each sample  should be labeled with name , date of birth  and/or MRN , and sample ID 
number  using permanent ink . Label each sample with name and date of birth and/or 
MRN at the time of sample collection . Add the sample ID number for each sample after 
you complete the laboratory requisition forms.  The sample ID numbers fo r rWGS are 
generated by the RCIGM ordering portal at the time the online requisition is completed.  
The sample ID numbers for NewbornDx  will be generated manually by the site as 
instructed in the MOP.  
 
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
53 Blood Sample Storage Conditions until Shipment  
Keep the blood samples refrigerated at 4◦C until the time of shipment  (up to 5 days) . Do 
not freeze. The DBS may be kept at room temperature until shipment.  
 
Order NewbornDx  and rWGS  
Complete the requisitions for each laboratory  as follows and according to the MOP :  
The site 
shipping 
samples  Requisitions 
to complete  Process  
All sites 
(except 
Mount 
Sinai ) Athena  
Diagnostics  Complete the paper  Athena requisition according to the 
MOP , keep a copy in the  infant’s  research file  and 
include it when shipping samples to Athena . 
RCIGM  Login to the HIPAA -compliant RCIGM ordering portal and 
complete the online test requisition form  according to the 
instructions in the MOP. The RCIGM ordering portal will 
1) assign a RCIGM Portal Case ID and 2) generate a 
RCIGM sample ID code  for each sample . Print the 
requisition form , keep a copy in the infant’s research file 
and include it when shipping samples  to RCIGM .  
Mount 
Sinai  Athena  
Diagnostics   Complete the paper  Athena requisition  according to the 
MOP , keep a copy in the infant’s research file  and 
include it when shipping samples to Athena.  
RCIGM  Login to the HIPAA -compliant RCIGM ordering portal and 
complete the online test requisition form  according to the 
instructions in the MOP . The RCIGM ordering portal will 
1) assign a  RCIGM  case ID and 2) generate a RCIGM 
sample ID code  for each sample . Print the requisition 
form, keep a copy in the infant’s research file and include 
it when providing samples to Sema4 (don’t ship  whole 
blood  samples  to RCIGM) .  
Sema4  Complete the paper -based Sema4 requisition , keep a 
copy in the infant’s research file  and include both the 
Sema4 requisition and the RCIGM requisition when  
providing samples to Sema4 . 
Sema4  RCIGM  Include  the RCIGM requisition completed by and 
received from Mount Sinai when shipping the  DNA 
samples to RCIGM . 
 
Be sure to in dicate in the appropriate fields on all requisitions whether or not  the 
parent /guardian  opted -in to receive secondary findings for the infant  and if each 
biological parent opted -in for their own secondary findings.  
 
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
54 Provision of Clinical Information to the Laboratories  
HPO Terms  will be provided by the site to the laboratories to inform the data 
interpretation of the genomic sequencing  (refer to section 6.1.1, Phenotype Extraction  
and instructions in the MOP ). It is the responsibility of the site to ensure the infant ’s 
clinical condition is monitored while NewbornDx  and rWGS are in process. Refer to the 
MOP about how to communicate any changes  (either positive or negative)  in the 
phenotype of the infant  after the HPO terms  are sent . 
 
Laboratory Notification of Urgent Testing  
If the site PI determines an infant  requires urgent  testing (refer to urgent testing criteria 
above), the site  should order a n “ultra-rapid ” WGS test in the RCIGM portal and contact 
Athena  at the time of sample shipment to inform them of urgent testing . Mount Sinai 
should contact Sema4 to extract the DNA and ship it to RCIGM as quickly as possible . 
How to notify the laboratories of urgent testing is detailed in the MOP.  
 
Blood Sample Shipment  
The shipping address, shipping conditions and when to delay shipment of the infant’s 
sample to obtain parent samples is described in the MOP. Only lab oratory  personnel 
with International Air Transport Association (IATA) certification should package /ship 
specimens.  Ship samples overnight delivery. RCIGM must  receive the blood samples 
by 10AM PST  to ensure it is on that day’s sequencing run.  Athena Diagnostics d oes not 
accept samples on Sundays.  RCIGM will receive samples on  Sunday if the ordering 
provider determines that the patient is critically ill and requires results as fast  as 
possible ; contact RCIGM  prior to shipping samples . 
 
Receiving 
Lab Enrolling 
Site What the Enrolling Sites Ship  
Athena  All Sites  o Infant: minimum of 2 Dried Blood Spots on one DBS Card  
o Mother: 2ml of whole blood in one EDTA tube  
o Father: 2ml of whole blood in one EDTA tube  
o Athena Requisition Form  
RCIGM  All sites 
except 
Mount 
Sinai  o Infant: 0.5ml whole blood in each of two EDTA tubes  
o Mother: 0.5ml whole blood in each of two EDTA tubes  
o Father: 0.5ml whole blood in each of two EDTA tubes  
o RCIGM Requisition Form  
Sema4*  Only Mount 
Sinai  o Infant: 0.5ml whole blood in each of two EDTA tube s 
o Mother: 0.5ml whole blood in each of two EDTA tubes  
o Father: 0.5ml whole blood in each of two EDTA tubes  
o Sema4 Requisition Form  
o RCIGM Requisition Form  
*Sema4 will isolate DNA from the blood samples , ship DNA  aliquots  for the infant  and each 
biological parent  to RCIGM and keep an aliquot at Mount  Sinai for possible confirmation testing.   
 
 
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
55 Tracking of Samples  
When the samples are shipped, the site research team should retain the tracking 
number for each shipment to confirm the package arrived at the applicable laboratory. 
Sites should send the  courier name and  tracking number applicable to Athena (Quest)  
and RCIGM via the email addresses provided in the MOP.  
 
Data Collection and Entry into the  REDCap  System  
The following i nformation from the infant’s medical record entered  into REDCap  by staff 
at each  enrolling  site. Enrolling sites will have access to data entered into REDCap  for 
infants at their own site. The study -wide co -PIs (Davis/Maron) and monitoring staff will 
have access to all data in REDCap .  
 
Refer to the detailed grid of Data eCRFs in section 1.3 Schedule of Activities  and the 
eCRF Instructions . Information collected and entered into the REDCap  database for 
enrolled infants will in clude:  
 identifiers (date of birth, date of hospital  admission , dates of tests/procedures , 
parent email address  if the parent wishes to complete follow -up surveys online  – 
this email is not release d or used outside of this study  and will be removed when 
de-identifying the dataset ) 
 birth information ( mode of delivery, birth weight , APGAR score, newborn 
screening results, pregnancy complications)  
 phenotypic information (clinical symptoms, clinical presentations , HPO terms )  
 clinical information (diagnoses, laboratory and imaging test results  including 
clinical genetic testing results ) 
 clinical genetic tests that would have been done if this research study was not 
available  
 genetic testing results as a result of study participation  
 any actions because of the research genetic test results  
 treatments ( surgical procedures  and medications ) 
 hospital billing information ( CPT codes, billing data)  
 medical visit, emergency room, hospitalization, procedures, treatments  post 
discharge home  
 quality -of-life assessments  
 date and cause of death, if applicable  
 adverse events  
 
Data for this study will be collected at the following time points: at enrollment, following 
return of results, at time of an adverse event, at transfer, discharge home, withdrawal , 
or death  and then monthly after discharge until the infant turns one-year CGA.   
 
Upload of Source Documents to the REDCap  System  
Scanned source documents will be uploaded to the REDCap system for remote 
monitoring. Copies of m edical records or source documents should be redacted of 
name and MRN or other account numbers, coded with  the Infant  Study ID, scanned to a 
PDF file  and uploaded to REDCap .  
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
56 Genomic Sequencing  Results  
Please refer to Section 6.1 Description of Study Intervention for details regarding the 
genomic sequencing methods that will be completed.  Results of the infant’s genomic 
testing will be shared with the research team, clinical team, the parent /guardian (s), and 
placed in the  infant ’s medical record as follows:  
Type of 
result  Result reported by laboratory  Action at site  
Provisional  
Positive  
Result  Diagnostic findings related to 
phenotype - pathogenic variant( s) 
in genes interpreted to be 
responsible for, or contributing to, 
the infant ’s phenotype will be 
reported  (classification of 
pathogenic or likely pathogenic) . A 
provisional result means the result 
has not been  confirmed. A 
provisional result is only given if 
waiting for confirmation testing 
would put the infant at risk for 
significant morbidity or mortality  (a 
treatment is available and a delay 
would cause irreversible harm) . 
For all provisional results, 
confirmation testing will 
subsequently be performed.  The enrolling site will receive 
management guidance by the 
laboratory and consult with their 
clinical genetics team. Provisional 
results will be entered in the 
infant ’s medical record under a 
research note. The research note 
will outline what provisional resul ts 
were reported. Provisional results 
may guide the implementation of 
an intervention for the infant . 
Following clinical confirmation of 
results, a clinical report of the final 
result will be placed in the medical 
record. In the event that the 
positive fin ding cannot be 
confirmed, a research note will be 
added to the medical record to 
facilitate communication among 
multiple specialty services.   
Confirmed 
Positive 
Result  Diagnostic findings related to 
phenotype - pathogenic variant(s) 
in genes interpreted t o be 
responsible for, or contributing to, 
the infant ’s phenotype will be 
reported  (classification of 
pathogenic or likely pathogenic) . 
The result has been  confirmed (for 
example with Sanger or qPCR ). 
All positive results will be 
confirmed prior to return t o the 
enrolling site with the exception of 
a provisional result.  Confirmed positive  results will 
yield a clinical diagnosis, a referral 
to clinical genetics and reported in 
the medical record. Results may 
guide the implementation of an 
intervention for the  infant . 
Confirmed 
Variant of 
Unknown 
Significance 
(VUS)  A variant for which the clinical 
significance is unknown. The 
variant detected may or may not 
explain the infant ’s current clinical 
symptoms.  The variant has been Suspicious VUS reported by the 
laboratories will be reported in the 
medical record. In the future, a 
variant may become known to be 
significant, and the parent/  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
57 Type of 
result  Result reported by laboratory  Action at site  
confirmed.  Only suspicious VUS 
(where the phenotypic fit is very 
good and/or functional 
confirmatory tests are readily 
available and/or the results are 
actionable) will be reported by the 
laboratory.  guardian(s) of the infant  will have 
this information to provide to their 
personal physician.   
Negative 
Result  The result that pathogenic variants 
associated with the infant ’s clini cal 
phenotype  were not detected  
(classification likely benign or 
benign) . Negative results will be reported to 
the medical record in accordance 
with standard care for clinical 
laboratories to reflect the clinical 
testing ordered.  
Secondary / 
Incidental  
Finding for 
the Infant  Variant(s)  not thought to be 
related to the infant ’s current 
symptoms but still important for 
the person’s health will be 
reported if 1) the parent /guardian  
opted-in to receive additional 
results  for the infant , 2) the onset 
of the disorder may occur in 
childhood , and 3) at least one of 
the following: a) the disorder is 
medically actionable (available 
treatment  to cure or ameliorate 
symptoms  or preventative 
measure), or b) The disorder is of 
a gene on the “ACMG list” of 
genes recommended  for reporting 
of secondary findings at the time 
of testing.  Upon receipt of a report with a 
secondary /incidental  finding for 
the infant , the site will verify on the 
signed ICF that the 
parent /guardian( s) opted -in to 
receive additional results  for the 
infant . The result will be given at 
the same time as a primary finding 
for the infant . 
Secondary / 
Incidental  
Finding for 
a Biological 
Parent  If a duo or trio is done, variant(s)  
not thought to be related to the 
infant ’s current symptoms but still 
importan t for the biological 
parent ’s health will be reported if 
1) the biological parent  opted-in 
during the informed consent 
process to receive additional 
results  and 2) the variant is of one 
of the 59 genes recommended by 
the ACMG to report back as 
secondary fi ndings.  Secondary 
findings for a biological parent  will Upon receipt of a report with a 
secondary /incidental  finding for 
the biological parent , the site will 
verify on the signed ICF that the 
biological parent s opted -in to 
receive additional results . The 
result  will be given to the biological 
parent s by the enrolling site PI, 
study geneticist or genetics 
counselor and a referral to clinical 
genetics will be made.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
58 Type of 
result  Result reported by laboratory  Action at site  
be returned in a separate report 
from the report issued for the 
infant  and the biological parent  
report will not be put in  the infant ’s 
medical record . The report of a 
secondary finding  for a biologic al 
parent  will be issued to the 
enrolling site PI.  
 
Clinical Laboratory Report  
Standard clinical laboratory reports of results will be issued from Athena  Diagnostics  
and RCIGM. The report of results will include: test result [positive (diagnosis), negative, 
variant of unknown significance], sequence variants detected (gene and transcript, 
chromosome, genomic coordinates, variant, confirmation status) , variant interpretation, 
gene information, references, recommendations, test methodology, test limitations, 
regulatory disclosures, laboratory contact information, CLIA #, CAP #.  Exception: Until 
conditional New York State  CLIA certification and rWGS  approval is obtained, RCIGM 
will issue a research report  for subjects from Mount Sinai . For results that are confirmed 
by Sema4 , Sema4  will issue a stan dard clinical laboratory report.  
 
Raw Sequencing Data  
Under California law  (Assembly Bill No. 375) , sub jects have the right to obtain their own 
sequencing data from for -profit companies . Athena (Quest)  Diagnostics is required to 
make sequencing data available upon request if paid a data recovery fee  by the subject . 
This information is included in the informed consent form.  While not mandated per law, 
raw data  can be downloaded from the RCIGM portal for 60 days after the results are 
returned . After this time, sequencing data can be obtained by request with a turn -around 
time of approximately 1 week.  
 
At the end of the study, VUS may be re-analyzed to see if gains in the understanding of 
genotype and phenotype correlation have occurred over the length of the study  which 
changes the infant’s results (i.e. a VUS becomes positive). In such a case, the site will 
attempt to notify the parent/guardian(s) .   
 
Future Use of Specimens and Sequencing D ata 
DNA may be stored for further testing if necessary for the management of the infant . 
Stored DNA will be destroyed at the conclusion of the study  per section 10.1.4, Future  
Use of Stored Specimens and Data . 
 
 
 
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
59 Process for the laboratory to  return results to the research team  and the medical record  
 
Notification of a Provisional Result:  
If any of the laboratories have a positive result requiring provisional reporting, the 
laboratory must:  
1. Call three parties: 1) the attending physician taking care of the infant, 2) the site 
PI and 3) study -wide co -PI Dr. Jill Maron. The lab will use the contact information 
provided by the site on the requisition to reach the attending physician of record. 
Theref ore, the site will determine the best number (e.g. the clinical unit phone 
number where the infant is admitted or the beeper/phone that the NICU fellow 
holds 24/7). The phone numbers for each site PI and Dr. Maron are listed in the 
MOP. Provide  verbal provisional result and  management guidance with read 
back. The notifying  laboratory will document the person to whom the result is 
reported  and the date and time of notification (refer to the form, “ Documentation 
of Verbal Result Returned ”).  
2. Send an encrypted email of a PDF of the  provisional result  report to 1) the 
physician of record, 2) the site PI/research team, 3) the study -wide Co -PIs and 
project manager . The email addresses to reach the physician of record should be 
obtained during the verbal report. The RCIGM portal will be configured to 
automatically trigger a copy of the email alert to the site study team and the 
study -wide Co -PIs. Athena (Quest)  will refer to the  email addresses for each site 
PI and Dr. Maron listed in the MOP but these should also be included on the 
requisitions.  Refer to the MOP for contact information.  The provisional result will 
not be digitally faxed directly into the EMR.  
 
The site will enter p rovisional results in the infant ’s medical  record under a research 
note. T he research note will outline what provisional results were reported. Following 
clinical confirmation of results, a final clinical report will be placed in the medical 
record. In the event that the positive finding cannot be  confirmed, a research note 
will be added to the medical record to facilitate communication among multiple 
specialty services.  
 
Notification by the Laboratory of a Confirmed Positive Result , Negative Result or 
Suspicious VUS: 
The laboratory must:  
1. Send an encrypted e mail of a PDF of the report to 1) the site research team  and 2 ) 
the study -wide Co -PIs and project manager .  Refer to the MOP for contact 
information.  
2. In the case of 1) a confirmed positive result  or 2) a final result that has the potential 
for immediate implications for the infant ’s management (i.e. provisional result that is 
not confirmed) , call the attending physician of record caring for the infant . Provide 
verbal  results with read  back . The notifying laboratory will document the person to 
whom the result was reported, and the date and time of notification (refer to the 
form, “Documentation of Verbal Result Returned”). After the site is contacted , the 
laboratory must call the site PI and  Dr. Maron.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
60 3. During the course of this study, we intend  to move to a process in which the 
laboratory issues the report directly to the infant’s EMR by digital fax. For infants 
from Mount Sinai, the RCIGM report will be sent to the Mount Sinai PI, not the 
infant’s EMR, for input into the subject’s research file. After completion of 
confirmation testing by Sema4, if applicable, the Sema4 CLIA -certified report will be 
sent to the infant’s EMR.  
 
Notification  by the Laboratory  of Secondary Findings  
1. If the parent /guardian (s) opted -in to receive secondary findings for the infant, the 
laboratory will report secondary findings  as described in section 6.1.1  in the 
return of results for the infant .  
2. If a biological parent  opted -in to receive secondary findings for him or herself, the 
laboratory will return secondary finding s for the individual biological parent  as 
described in section 6.1.1 in a separate report from the test result for the infant . 
This report will not be sent to the infant ’s EMR. It will be sent to the site PI.  
 
Process for returning results to the medical record  
It is intended for the report of results to be sent Athena  and RCIGM directly to the 
infant ’s EMR  via digital fax ; however , the enrolling site may need to manually deposit 
the report in the medical record until that process  is completed. The enrolling site is 
responsible for ensuring  that the  clinical laboratory re ports appear  in the infant ’s medical 
record . If the final results are discordant, all reports will still be placed in the medical 
record and a note should  document how the results will be used in clinical care. In the 
case of infant s enrolled at Mount Sinai, only results by a N ew York  State CLIA certified 
lab of a N ew York  State approved or conditionally approved test will be put in the 
infant’s medical record .  
 
Clinical genetics and related sub -specialty notes will be placed in the medical record per 
SOC.  
 
Adjudication of Discordant Results  
If the final results of NewbornDx and rWGS or the confirmation test results done at 
Sema4 are  discordant, adjudication processes, as outlined in the MOP, will be followed. 
If results are discordant due to variant classification, the laboratories will each provide 
the evidence supporting their result and variant classification. This summary will be  
given to the enrolling site PI to share with the clinical team; a subsequent phone call 
with the labs may be arranged upon request from the site. The clinical team  caring for 
the infant is in the best position to determine if one result best explains the phenotype of  
the infant and their view will be captured in the study data. Additionally, a subset of the 
study geneticists on the steering committee who are independent of the labs will review 
the redacted lab reports and lab summaries and provide what the y think is the most 
accurate result for an additional study endpoint. Senior lab personnel are available for 
questions by the steering committee. The opinion of the steering committee members 
may be shared with the enrolling site upon the site’s request.  Regardless of whether or 
not results between the tests are concordant, both the NewbornDx report and the rWGS 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
61 report will be put in the infant’s medical record. A note should be placed in the medical 
record to document how the results will be used in clinic al care.  
 
Communication with the Physician of Record and the Infant’s Parent/Guardian(s)  
The site should wait until results from both NewbornDx and rWGS are returned before 
speaking with the parent/guardian about  the results as long as  waiting would not harm 
the infant (i.e. the result is not provisional or the infant does not require urgent testing).  
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
62 Coordination Between Study 
Team and Physicians of 
Record re: Results  Qualifications of   Personnel 
providing Genetic Results 
to Parents/Guardians  Qualifications of   Personnel 
providing ongoing related 
information to 
parents/guardians  Providing Results to 
Parents/Guardians w hen an 
Infant is Discharged Home 
Prior to Return of Results  
The site PI/sub -I will speak 
with the physician of record 
and suitable subspecialists 
(for example, genetics, 
neurology, cardiology, etc.) at 
the time each test result is 
returned in order to review 
results and formulate a plan 
prior to returning a result to 
the parent/guardian.  
 
The PI and/or sub -I at all 
sites are neonatologists or 
geneticists.  
 
If the patient is discharged 
home prior to the return of 
results, the primary 
pediatrician should be 
contacted  along with hospital 
clinical and research 
personne l. 
 Results will be disclosed to 
the family with as many 
members of the clinical 
team caring for the patient 
present as possible. At a 
minimum, each site will 
include one or more of the 
following: attending clinical 
geneticist, attending 
physician of recor d, 
attending neonatologist or 
geneticist who is a member 
of the study team. 
Additional attending sub -
specialists relevant to the 
particular genetic condition 
and genetic counselors 
may also participate in 
providing results to families. 
If clinical practice  at a 
particular site is for licensed 
genetic counselors to return 
results without an attending 
physician as described 
above, the licensed genetic 
counselor may do so.  Recommendations to the 
family about changes in 
management or further 
genetic testing wil l be 
addressed by the physician 
of record as well as clinical 
genetics and other sub -
specialties per standard -of-
care.  
 
If a genetic problem exists 
that can be treated but does 
not need to be treated in the 
neonatal period, a referral to 
outpatient clinica l genetics 
will be made.  
 
 It is strongly recommended 
that positive results or a VUS 
be disclosed in -person 
followed by a referral to a 
clinical geneticist. Depending 
on the need for timely action 
based on the results, it may 
be appropriate  to return the 
result a t the time of the next 
outpatient clinical genetics  or 
related subspecialist  
appointment or to ask the 
family to come into the site to 
meet with the site PI to hear 
about the study results.  
Under  extraordinary 
circumstances (where the 
family lives hours away 
and/or has moved out of 
state ), diagnostic or VUS 
results may be given by 
phone  along with a clinical 
genetics referral . It is 
acceptable to convey 
negative/no finding results by 
phone with an offer for follow 
up genetic counseling visit.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
63 Communication with a Biological Parent about a Parent Secondary Finding  
Upon the receipt of a report with a secondary finding for a biological parent by the site 
PI, the site will verify on the signed ICF that the biological parent opted -in to receive 
secondary findings. The result will be given to the biological parent by the  enrolling site 
PI, study geneticist or genetics counselor and a referral to clinical genetics will be made. 
Some sites may opt to create a medical record for each biological parent and scan the 
consent and individual parental secondary findings to that me dical record.  
 
Genomic Sequencing Clinical Utility  Survey  
At discharge home or within one month after the return of results for  infants who 
discharge home prior to the return of results, the physician  of record at the time the 
results are returned will  be asked to complete a brief survey regarding the clinical utility 
of the genomic testing.  The one physician under w hom the infant is admitted at the time 
results are received will receive the survey (i.e. neonatologist if the infant is in the NICU, 
pedia tric critical care attending if the infant is in the PICU).  The survey will be sent via 
email or a paper copy handed to the physician. The goal of the survey is to identify what 
changes were made to the immediate management of the infant  as a result of testing as 
well as the general utility of the diagnosis. If the infant is discharged (home or death) 
prior to return of results, the Clinical Utility Survey should be completed by the clinical 
geneticist, most relevant subspecialist or by t he site PI after speaking with the 
pediatrician (if baby was discharged home).  
 
Parent /Guardian  Contact Information , Medical Record Release and Diaries  at 
Transfer/Discharge Home  
The parent /guardian( s) will fill out a contact information form with multiple methods of 
contact to ensure we are able to reach the parent/guardian or primary care provider until 
the infant  is 1 year CGA . A quality of life  (QoL) instrument (The Optum™ SF -12v2® 
Health Survey)  and the Child Visual Analog Scale will be administered.  
 
Billing Information  
At transfer to another facility and/or discharge home, the enrolling site research staff will 
obtain the final hospital costs and charges , and all physician CPT codes,  for the infant’s  
hospitalization.  
 
Parent /Guardian  Interview  and Medical Record Acquisition  
Following  transfer of facility or  discharge home, study staff will contact one 
parent /guardian  monthly to assess how the infant is progressing until 1 year CGA . The 
parent /guardian will be asked about any new testing, diagnosis, medications, medical 
visits or hospitalizations, and any missed days of work due to their child’s  disorder. 
Ideally, the parent will receive a link via email to complete the monthly parent survey 
online in the  REDCap  system; however, the parent/guardian may be contacted by e -
mail or phone per the parent/guardian’s preference. Self-reported QoL information will 
be collected from a parent /guardian  at 3-month intervals to infer the impact on the family 
of any prolonged illness.  The follow -up surveys  will be translated into Spanish. In the 
case of a parent/guardian who does not read English  or Spanish , the follow -up contact 
will need to be made with an interpreter by phone.  Upon request by the health 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
64 econ omics analysts and as permitted in the ICF, m edical records and billing information 
from any hospitalizations and any outpatient health care utilization  may be obtained 
from the provider institutions to complement parent/guardian self -report.    
 
8.3 SAFETY AND OTHER ASSESSMENTS  
 
Enrolling sites must actively monitor, identify and assess adverse events  (AE) in the 
study.  Identification of AEs will be based on review of the medical record, observation 
by study staff and by report during the parent survey/interviews. For each AE, the 
investigator will determination whether the adverse event is serious, provide the 
duration (start and end dates), the severity grade (mild, moderate, severe), the 
relationship to the study testing (unlikely, possibly, an d probably), action(s) taken, and 
the outcome. The AE assessment must be documented and retained with study files. 
The Investigator’s signature and date on the source document that supports the 
causality noted on the AE form ensures that a medically qualif ied assessment of 
causality was done.  
 
The laboratories conducting genetic sequencing for this study fall under the CLIA/CAP 
regulations. They continually monitor for errors and non -conforming events and will 
notify the study -wide PIs via phone/email of an  error/event that affected a result for the 
infant. They will also notify the study -wide PIs if a data breach were to occur. In these 
instances, the study -wide PI would file an adverse event , and notify the DSMB, IRB, 
and NCATS as required .  The laboratori es are not expected to report adverse events as 
described in sections 8.3 and 8.4 . 
 
8.4 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.4.1  DEFINITION OF ADVERS E EVENTS (AE)  
 
An Adverse Event for this study will only include  the following:  
 An untoward medical occurrence  related to obtaining the study blood samples  
 If findings for the infant thought to be secondary  at the time results are reported  
are given to the research team, clinician or parent /guardian  when the 
parent /guardian  did not opt -in to receive secondary findings for their infant  
 If secondary findings  for a parent  are reported to the research team, clinician or 
parent when the parent did not opt -in to receive parental secondary findings   
 Intervention based on inaccurat e result returned (testing error; provisional result 
not confirmed)  
 Intervention based on wrong result returned (human error, result not accurately 
matched up with the correct infant ) 
 Untoward event related to an intervention initiated due to the genomic testing 
results (intervention that would not have been initiated without the genomic 
testing results)  
 Loss of confidentiality  related to study participation  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
65  Any new untoward medical occurrence  related to study participation or the 
genetic sequencing  result s   
 A pre -existing condition that worsens in terms of frequency or intensity  and the 
worsening is due to study participation/genetic sequencing results  
 The infant dies due to error because the infant was enrolled in this study 
(erroneous result or misidentification)  
 
Events not reported as Adverse Events for this study:  
 A pre -existing condition at the time of enrollment  
 A pre -existing condition that worsens in terms of frequency or intensity but the 
worse ning is not related to study participation/genetic sequencing  
 A new untoward medical occurrence that is not related to study 
participation/genetic sequencing results and does not result in death  
 Death due to  natural causes before genetic testing  results  are returned (i.e. 
prematurity)  
 Death due to parent/guardian wishes to withdraw life sustaining treatment if an 
infant  is determined to have a  lethal condition by genetic testing  
 
8.4.2  DEFINITION OF SERIOU S ADVERSE EVENTS (SA E)  
 
An adverse event (AE) or suspected adverse reaction is considered "serious" if in the 
view of either the investigator or sponsor, it results in any of the following outcomes: 
death, a life -threatening adverse event, prolongation of existing hospitalization , a 
persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or a congenital anomaly/birth defect. Important medical events that 
may not result in death, be life -threatening, or require more prolonged hospitalization 
may be considered serious when they may jeopardize the infant and require medical or 
surgical intervention to prevent one of the outcomes listed in this definition.  
 
Events that are not related to study participation or genomic sequencing will not be 
captured as an SAE since the definition of an adverse event for this study requires a 
relation to genetic testing (rather than the underlying disorder).  
 
8.4.3  CLASSIFICATION OF AN  ADVERSE E VENT  
The PI or another licensed clinician who is a study member authorized on the 
delegation log will classify adverse events.  
8.4.3.1  SEVERITY OF EVENT  
  
The investigator should use the following definitions when assessing intensity of an 
adverse event:  
 Mild: Infant or a biological parent has minor findings but tolerates them well, and 
no or minimal intervention required  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
66  Moderate: Infant or a biological parent  experiences enough symptoms or findings 
to require intervention  
 Severe: Infant or a biological parent  experiences symptoms or findings that 
require signif icant intervention  
 
8.4.3.2  RELATIONSHIP TO STUD Y INTERVENTION  
 
All adverse events ( AEs) must have their relationship to the genomic sequencing  
assessed . The investigator will examine and evaluate the participant based on temporal 
relationship and his/her clinical judgment.  
 
The criteria below are intended as guidelines to assist the Investigator in assessing the 
likelihood of a relationship between the genomic sequencing testing and the adverse 
event. The greater the correlation with the components and their respective elements, 
the more likely the genomic sequencing testing caused the adverse event.  
 Exposure : Is there evidence that the infant or biological parent had the testing 
performed such as:  reliable history, patient records, assays run in applicable 
laboratories and results exist?  
 Time Course : Did the AE follow in a reasonable temporal sequence from 
performance of the testing? Is the time of onset of the AE compatible with the 
testing being performed?  
 Likely Cause : Is the AE not reasonably explained by another etiology such as an 
underlying disorder  or other host or environmental factors?  
 
The following scale of criteria may be used as a guidance (not all criteria must be 
present in order to be indicative of a relationship to study genomic sequencing ). 
 
Probably related to 
study genomic 
sequencing   There is evidence the infant or a biological parent had the 
genomic testing performed  
 The temporal sequence of the AE onset relative to genomic 
testing is reasonable  
 The AE is more likely explained by the genomic testing than 
by another cause  
Possibly related to 
study genomic 
sequencing   There is evidence the infant or a biological parent  had the 
genomic testing performed  
 The temporal sequence of the AE onset relative to genomic 
testing is reasonable  
 The AE could have been due to another equally likely cause  
Unlikely related to 
study genomic 
sequencing   There is evidence the infant or a biological parent  had the 
genomic testing performed  
 There is no temporal relationship to genomic testing  
 There is another more likely cause of the AE  
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
67 8.4.3.3  EXPECTEDNESS  
 
The investigator  will be responsible for determining whether an AE is expected or 
unexpected. An AE will be considered unexpected if the nature, severity, or frequency 
of the event is not consistent with the risk information previously described for the study 
intervention. An AE is considered unexpected if it is not consistent with the risk 
information described in the protocol.  
8.4.4  TIME PERIOD AND FREQ UENCY FOR EVENT ASSE SSMENT AND 
FOLLOW -UP 
 
AEs must be actively identified from the signing of the ICF until the infant reaches one 
year CGA . AEs must be followed until an outcome is known. All events that cannot be 
resolved by 30 days after the final assessment at 1 year CGA  will be considered 
resolved by convention and entered in the  REDCap  system.    
 
8.4.5  ADVERSE EVENT REPORTING  
 
Reporting of non-serious AEs must occur using the Adverse Event eCRF in the 
REDCap  system according to the following : 
Event  Timeframe for Site to Report  Timeframe for Study PI to Report  
AE, not serious  Site enters AE into EDC within 7 
business days of identification.     The study PI reports to the DSMB 
every 6 months and in the annual 
progress report to NCATS.  
 
8.4.6  SERIOUS ADVERSE EVEN T REPORTING  
 
Reporting of SAEs must occur using the adverse event eCRF in the REDCap  system 
according to the following:  
Event  Timeframe for Site to Report  Timeframe for Study -wide PI to 
Report  
SAE  Site reports to the study -wide PI 
within 24 hours of learning 
about the event . The study -wide PI will alert the  
DSMB chair within 24 hours  of 
learning about the event . If the SAE 
is also an unanticipated problem, 
the study -wide PI will also report to 
the central IRB and  NCATS  within 
24 hours of learning about the 
event.  
  
To ensure accurate clinical trial reporting and correct interpretation of safety signals, 
each death  will be examined to determine cause. This may be difficult in the preterm 
infant population as there are often multiple events which contribute to death. For the 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
68 purposes of this clinical trial, the investigator will attribute the cause of death to the AE 
which had the greatest medical contribution to death, regardless of whether or not the 
event was the most proximal. For example, if an infant  has a large intraventricular 
hemorrhage that leads to seizures and death, the death should be attributed to 
intraventricular hemorrhage, not seizures. The investigator should utilize all available 
information when attributing cause of death. Autopsy information should be utilized 
where a vailable to amend the adverse event report if needed. It is recognized that the 
death certificate may not reflect clinical trial procedures and thus may not match the 
cause of death attributed by the investigator. In the rare situation for deaths in which no 
single AE represents the greatest medical contribution to death,  the adverse event is 
listed as “Death not associated with an AE term” and one of the following causes must 
be selected: 1) death not otherwise specified (i.e. failure to thrive), 2) extrem e 
prematurity, 3) multi -organ failure, and 4) sudden death (no documentation of cause, 
includes Sudden Infant Death Syndrome). For cases in which the cause of death is 
unclear, the final determination as to which AE or organ system the death should be 
attributed will be determined by the DSMB.  
 
8.4.7  REPORTING E VENT S TO PARTICIPANTS  
 
The parent/guardian of an infant will be told of AEs/SAEs in the course of the infant’s 
clinical care  (i.e. untoward event related to treatment  initiated from sequencing results) 
or in the instance of an inaccurate  or wrong  result returned . If the risk of participating in 
the study change s, re-consent of the parent/guardian or of a biological parent will occur 
at the discretion of the  IRB and DSMB .   
 
 
8.5 UNANTICIPATED PROBLE MS 
 
8.5.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
 “Unanticipated Problems Involving Risks to Subjects or Others” (“UPIRSO”). An event 
is considered an UPIRSO when it meets all of the following criteria:  
  
(1) It is unexpected (in terms of nature, severity, or frequency) given (a) the research 
procedures that are described in the protocol -related documents, such as the IRB -
approved research protocol and informed consent document; and (b) the characteristics 
of the population being studied;  
 
Unexpected events cou ld be either medical or non -medical events.  
 
(2)  It is related or possibly related to participation in the research (i.e. there is a 
reasonable possibility that the incident, experience, or outcome may have been caused 
by the procedures involved in the re search);  
 
and, 
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
69 (3) It places subjects or others [e.g. study team members or relatives of a subject] at a 
greater risk of harm (including physical, psychological, economic, or social harm) than 
was previously known or recognized  
 
8.5.2  UNANTICIPATED PROBLE M REPORTING  
 
Certain types of events (as defined below) and including unanticipated problems 
involving risks to subjects or others must be  promptly  reported to the IRB:  
Event  Timeframe for Site to Report  Timeframe for Study PI to Report  
Certain types of 
events (as 
defined below)  Sites much report the event to 
the study -wide co -PIs as soon 
as possible but no later than 8 
working days after discovery or 
in the case of a death within 24 
hours of learning about the 
event.  The study PI will alert the central 
IRB, DSMB Chair, and NIH   as 
soon as possible after the event is 
discovered  by the site , but in all 
cases within 10 working days after 
discovery of the event  by the site . 
Reportable deaths, as described in 
this section,  must be reported  as 
soon as possible but in all cases  
within 72 hours after discovery  by 
the site.  
 
The following “certain types of events” must be promptly reported to the IRB:  
 
A. UPIRSO  (refer to definition in section 8.4.1)  
 
B. POTENTIAL SERIOUS OR CONTINUING NON -COMPLIANCE:     
 
Non-Compliance is defined by the Organization as the failure to follow the research 
protocol, federal, state, or local laws or regulations governing human subjects research, 
institutional policies, or  the requirements or determinations of the IRB.  Only incidents 
that may qualify as serious or continuing non -compliance must be promptly reported:  
 
(1) Serious Non -compliance is defined by the Organization as non -compliance that 
either (a) significantly h arms or poses an increased risk of significant harm to subjects 
or others, or (b) significantly compromises the rights and welfare of the subjects or the 
integrity of the Organization’s human research protection program.  
 
(2) Continuing Non -compliance is d efined by the Organization as a pattern of non -
compliance that significantly compromises the scientific integrity of the study or the 
rights and welfare of the subjects or the integrity of the Organization’s human research 
protection program.  When applyin g this definition, particular consideration may be 
given by the IRB to activity that recurs after a previous report has been evaluated by the 
IRB and corrective action has been instituted.  
 
C. OTHER EVENTS THAT REQUIRE PROMPT REPORTING:  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
70  
In addition  to the above, investigators must also promptly report the following:.  
 
 Potential Breaches of Confidentiality:  Any unauthorized disclosure of subject’s 
personally identifiable information.  Please Note: Potential breaches of 
confidentiality that involve prote cted health information (PHI) must also be 
reported promptly to the HIPAA Privacy Officer. Please see guidance for further 
detail.  
 Incarceration of a parent participating in this study  
 Unresolved Subject Complaints:  Complaints of subjects when the complai nt 
indicates unexpected risks or cannot be resolved by the research team.  
 Other events: There may be other events that should be promptly reportable to 
the IRB.   
 
Events that do not meet the above criteria should be summarized and reported to the 
IRB at t he time of continuing review.  
 
8.5.3  REPORTING UNANTICIPA TED PROBLEMS TO PART ICIPANTS  
Refer to section 8.3.7  
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
71 9 STATISTICAL CONSIDER ATIONS   
 
9.1 STATISTICAL HYPOTHES ES 
 
The analysis plan is descriptive. There will be no statistical hypothesis testing.  
 
9.2 SAMPLE SIZE  DETERMINATION  
 
The sample proportion and 95% CI for the binary outcomes of NewbornDx  and rWGS 
will be calculated. The table below shows the 95% confidence limits of the estimated 
proportion for a range of proportions, assuming the sample size is 400 compl eted 
infant s. For example, if the sample proportion is 0.05 for disorders detected by rWGS  
but not NewbornDx , the 95% CI will be 0.03 to 0.07.  Since the distribution of time to 
diagnosis is unknown, it is difficult to speculate as to the width of the conf idence interval 
for the mean or median. However, 40% to 60% (160 to 240 infant s) are expected to 
have a genetic diagnosis which is a sufficient number for a precise estimate.  
 
Table: Confidence Interval Limits with 400 infant s 
Proportion  Lower 
Limit  Upper 
Limit  
0.05  0.03  0.07  
0.10  0.07  0.13  
0.20  0.16  0.24  
0.30  0.25  0.35  
0.40  0.35  0.45  
0.50  0.45  0.55  
 
9.3 POPULATIONS FOR ANALYSES  
 
 ICF Dataset: All families who were approach ed for study participation  
 Intention -to-Treat (ITT) Dataset : all consented infant s 
 Modified Intention -to-Treat Dataset : all consented infant s for whom both 
NewbornDx  and rWGS genomic sequencing results were returned  
 Per-Protocol Dataset: all consented infant s who received both NewbornDx  and 
rWGS  (modified intentio n-to-treat dataset)  and completed the study period for the 
analysis of the primary and secondary objectives without clinically important 
protocol deviations. Clinically important protocol deviations will be identified and 
documented prior to the database l ock.  
 Time to Molecular Diagnosis Dataset: The Modified Intention -to-Treat Analysis 
Dataset excluding the infant s who did not have a confirmed positive result  
 Urgent Testing Dataset: All infant s who required urgent testing per section 8.1  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
72  Safety Analysis Dataset: All infant s for whom blood specimens were obtained or 
data collected  
 
9.4 STATISTICAL ANALYSES  
 
9.4.1  GENERAL APPROACH  
 All analyses will be descriptive. We will calculate the proportion and 95% CI among 
enrolled infant s with confirmed genetic disorders detected by NewbornDx , by rWGS, by 
NewbornDx  but not rWGS, and by rWGS but not NewbornDx . We will also calculate the 
95% CI for the ratio of the proportion detected by NewbornDx  relative to  the proportion 
detected by  rWGS69. Although dete ction by SOC is an exclusion criterion, some infant s 
will receive a diagnosis by SOC after enrollment. We will therefore also calculate the 
proportion and 95% CI of those receiving a diagnosis by SOC prior to the time that 
results from NewbornDx  or rWGS be come available. We will calculate the proportions 
and CIs for enrollees with no confirmed diagnosis  of a genetic disorder . These will be 
calculated at discharge and at 1 year CGA . We will calculate the proportion of infant s 
with conditions detected by NewbornDx  that were not listed as part of the differential 
diagnosis at enrollment. The same calculation will be performed for rWGS. We will 
calculate the positive predictive value (PPV) of NewbornDx  and rWGS (i.e. the 
proportion of positives that are conf irmed by Sanger or PCR).  
 
Because a “gold standard” does not currently exist, it will not be possible to calculate 
the negative predictive value (NPV), sensitivity, or specificity of NewbornDx  or rWGS. 
We will calculate the proportion for which there was clinical utility from genomic testing  
(change in drug treatment, surgical treatment, imaging, subspecialty consult, diet,  other 
treatment, and redirection  of care and/or withdrawal of life sustaining treatment ). We will 
also calculate the proportion of tes ting where trios were ultimately required to confirm a 
diagnosis for rWGS) and if this approach increased the number with a confirmed 
diagnosis . Kaplan -Meier (K -M) curves will be used to estimate the time from enrollment 
to molecular diagnosis (separately for NewbornDx  and rWGS) including all enrolled 
infant s and excluding infant s with out a diagnosis of a genetic disorder and those 
diagnosed by SOC before genomic results are returned . The analysis will count as 
positive only those diagnoses that  are eventually confirmed. We will also use K -M to 
estimate age at diagnosis and survival. A model will be developed to predict, using 
information available at the start of symptoms, whether the NewbornDx  ultimately yields 
a confirmed and actionable diagno sis. Such a model could help to further target 
NewbornDx  to the population that would benefit most from it, especially if the model 
discrimination is high (c -statistic greater than .90). The model will be validated using 
bootstrap validation.  
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
73 9.4.2  ANALYSIS OF  THE PRIMARY EFFICACY  ENDPOINT(S)  
 
Primary Endpoints  Definition  Scale and 
measure  Populations for 
which the 
analysis will be 
conducted  
A confirmed 
positive result  
detected by 
NewbornDx   If NewbornDx  and the 
confirmatory test have the 
same positive finding  Binary: Yes/No ; 
single endpoint  Modified 
Intention -to-
Treat Dataset  
A confirmed 
positive result  
detected by rWGS  If rWGS and the confirmatory 
test have the same positive 
finding  Binary: Yes/No; 
single endpoint  Modified 
Intention -to-
Treat Dataset  
Time  to a positive 
result  by 
NewbornDx  *  Among those who have a 
confirmed positive result  at one 
year CGA by NewbornDx , 
rWGS, or another genetic test , 
comparison of date/time of 
sample collection to date/time 
of completion of NewbornDx  
prior to confirmation testing  Interval: Hours; 
single endpoint  Time to 
Molecu lar 
Diagnosis 
Dataset  
Time  to a positive 
result by rWGS *  Among those who have a 
confirmed positive result  at one 
year CGA  by NewbornDx , 
rWGS, or another genetic test , 
comparison of date/time of 
sample collection to date/time 
of completion of rWGS  prior to 
confirmation testing  Interval: Hours; 
single endpoint  Time to 
Molecular 
Diagnosis 
Dataset  
Time to a result by 
NewbornDx * 
 Among all babies tested, 
comparison of date/time of 
sample  collection to date/time 
of completion of NewbornDx  
prior to confirmation testing  Interval: Hours; 
single endpoint  Modified 
Intention -to-
Treat Dataset  
Time to aresult by 
rWGS *   Among all babies tested, 
comparison of date/time of 
sample collection to date /time 
of completion of rWGS  prior to 
confirmation testing  Interval: Hours; 
single endpoint  Modified 
Intention -to-
Treat Dataset  
Time from 
enrollment to a 
positive result  Among those who have a 
confirmed positive results at 
one year CGA by NewbornDx , 
rWGS  or another genetic test, Interval: Hours; 
single endpoint  Time to 
Molecular 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
74 Primary Endpoints  Definition  Scale and 
measure  Populations for 
which the 
analysis will be 
conducted  
detected by 
NewbornDx * comparison of date/time of 
informed consent to date/time 
of completion of NewbornDx  
prior to confirmation testing  Diagnosis 
Dataset  
 
Time from 
enrollment to a 
positive result  
detected by rWGS * Among those who have a 
confirmed positive results at 
one year CGA by  NewbornDx ,  
rWGS, or another genetic test, 
comparison of date/time of 
informed consent to date/time 
of completion of rWGS  prior to 
confir mation testing  Interval: Hours; 
single endpoint  Time to 
Molecular 
Diagnosis 
Dataset  
Clinical utility of 
genomic 
sequencing  If clinical action was taken due 
to return of results  
 
Time from result to action 
taken  
 
Types of clinical actions taken 
(i.e. surg ery, medication)  
 
Clinician opinion of utility  Binary: Yes/No  
 
 
Interval  
 
 
Categorical  
 
Ordinal  Modified 
Intention -to-
Treat Analysis 
Dataset  
If trio testing was 
required to obtain a 
diagnosis for 
rWGS  If Trios were done  
 
 
If Trios increased diagnostic 
yield Binary: Yes/No; 
single endpoint  
 
Binary: Yes/No; 
single endpoint   Modified 
Intention -to-
Treat Analysis 
Dataset  
If enrollees did not 
receive a diagnosis  No confirmed diagnosis of a 
genetic disorder identified by 
any of the genomic sequencing 
tests  Binary: Yes/No; 
single endpoint  Modified 
Intention -to-
Treat Analysis 
Dataset  
*The infants who met the criteria for urgent testing may be analyzed separately.  
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
75  
9.4.3  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  
 
Secondary Endpoints  
1. One-year cost-effectiveness of NewbornDx  and rWGS compared with SOC 
testing, from a societal perspective  
2. Lifetime year cost -effectiveness of NewbornDx  and rWGS compared with SOC 
testing, from a societal perspective  
 
We will conduct an economic evaluation that will compare costs and  health outcomes 
for infants with suspected genetic disorders who undergo: 1) traditional standard of care 
diagnostic testing, 2) NewbornDx , or 3) rWGS. One-year post-identification outcomes 
for NewbornDx  and rWGS will be estimated from trial data, while out comes for standard 
of care will rely on retrospective chart review .  We will use simulation  modeling  to 
extend our projections beyond 1 -year post identification to a lifetime time horizon.  
 
In Trial Data Collection for NewbornDx  and rWGS:  
This clinical trial provides a unique opportunity to examine observed health outcomes, 
care utilization , and family resource use for infants  being evaluated for a suspected 
genetic disorder. During the trial, charge  and cost  data will be collected from the total 
hospital bill at discharge home from the index hospitalization in which the infant is 
enrolled in the study. Following discharge, the parent will be contacted every 30 -days to 
collect resource utilization related to medica l visits, hospitalizations, diagnostic tests, 
labs, procedures, and medications administered after discharge home until one year of 
age corrected for prematurity. Data will also be collected on: 1) mother and father lost 
work days; and 2) observed health o utcomes, including death, diagnoses, and the 
timing of diagnosis. We will use a quality of life instrument to measure parental quality of 
life at monthly follow -up and to infer the value parents place on avoiding adverse health 
conditions. We will also col lect parent -reported quality of life of the infant using a visual 
analog scale . Health economics practice guidelines call for inclusion of such outcomes, 
particularly in child health intervention evaluations59,60. 
 
Assessment of  SOC  testing  
As no infant  in our trial  will only receiv e SOC  testing only (i.e., without NewbornDx  and 
rWGS), we will estimate standard of care testing outcomes (costs, diagnostic f indings, 
health outcomes) by  using a retrospective chart review.   
In the retrospective chart review , we will collect resource utilization and health care 
outcome data from  300 infants  born 12 -18 months prior to the start of the  study who had 
a genetic evaluation , but did not receive NewbornDx and rWGS . We chose infants  born 
in this timeframe to minimize differences between  contemporary clinical practice and 
clinical practice received by our retrosp ective cohort, hence maximizing the 
genera lizability of our retrospective data to contemporary settings.   
 
 
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
76 Simulation: Extending outcome estimates to a life time time horizon   
Following data collection, we will use simulation modeling to estimate outcomes (cost, 
and health outcomes) for all strategies: NewbornDx , rWGS and standard of care 
diagnostic testing over a 1 -year and lifetime horizon. For each strategy, the simulation 
model will project disorder progression based on estimated health state transition 
probabilities. By associating each health condition (or “health state”) with a “utility 
weight” (QALYs gained per year in that state) and annual cost, the simulation will track 
hypothetical infant s and sum QALY gains and incurred costs. Repeating this process 
with a large number of simulated infants  will yield estimated population health and cost 
outcomes. Costs and utility weights will be estimated from trial data, and previously 
published estimates, making the assumption that these values depend only on the 
infant ’s health state and not on the diagnostic testi ng technology. Thus, we assume that 
the costs and utility weight estimates apply to infant s undergoing any of the three 
diagnostic testing approaches.  
 
Since NewbornDx  and rWGS will identify a large number of disorders, disorders will be 
grouped based on estimated life expectancy and long -term severity. We will identify 
“disorder groups” by reviewing available data and literature on the expected outcomes 
of each identifiable disorder in conjunction with expert clinical judgment. We will also 
identify health  states that appropriately represent the possible outcomes for each 
“disorder group” following review and synthesis of available evidence with input from our 
Steering Committee and DSMB.  
 
Our lifetime simulation model will require: 1) classification of he alth states that describe 
health outcomes associated with each study strategy (e.g. disorder, disability, death); 2) 
health state transition probabilities, which represent the likelihood that simulated 
patients will develop specific disorder  and disability  outcomes, conditional on their 
assigned strategy; 3) health state costs, which include both health care associated with 
a specific health state and other societal costs; and 4) health state utilities, which 
represent health state preferences for avoiding adverse health outcomes. For the time 
period extending beyond the 1 -year CGA trial duration, we will identify model transition 
probabilities, health state costs, and health utilities from existing primary datasets and 
the literature. For many genetic disor ders, the literature reports limited long -term follow 
up data that appropriately account for expected differences in health outcomes due to 
differences in time to diagnosis. Available data will guide short -term extrapolation 
beyond our trial timeframe. For  long-term time periods for which there are no 
informative data, we will draw on expert opinion, and conduct appropriate sensitivity 
analyses to characterize the impact of the attendant uncertainty. Health state costs will 
include the health care and socie tal costs (e.g. family costs, special education). We will 
estimate health care utilization, family time and other resources use for each health 
state from available data sources and then multiply these utilization estimates by 
national unit prices. We will  also estimate child health state utilities using available data 
and will include utility values for parental quality of life when possible.  
 
Cost-effectiveness analysis: With simulation findings corresponding to the 1 -year CGA 
trial follow -up period and for extrapolation to a lifetime horizon, we will: 1) calculate 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
77 aggregate population costs and health outcomes (QALYs) for each trial strategy; 2) rank 
the strategies from least to greatest aggregate population health (total QALYs ); and 3) 
calculate incremental QALYs and costs for the second strategy (compared to the first) 
and for the third strategy (compared to the second). Incremental QALYs are, by our 
sequencing of these comparisons, non -negative. If corresponding incremental c osts are 
likewise non -negative, an incremental cost -effectiveness ratio (ICER) (incremental costs 
divided by incremental QALYs) will be calculated in a similar fashion. If incremental 
costs are negative in either case – that is, if either strategy reduces costs while 
improving health relative to its comparator – we refer to this strategy as “cost -saving”.  
 
Secondary 
Endpoint  Definition  Scale  Populations for which 
the analysis will be 
conducted  
Satisfaction of the 
web-based clinical 
reference database  Usefulness of information  
 
Ease of use of the clinical 
reference database  Categorical  
  Medical providers who 
use the clinical 
reference database  
after it is built  
 
In order to qualitatively assess the impact of the intervention, we will collect surveys 
from medical  providers across all sites. This survey will be submitted to the IRB prior to 
implementation.  
 
9.4.4  SAFETY ANALYSES  
 
All-cause mortality will be evaluated at  discharge  home  from the hospitalization during 
which enrollment occurs  and at one-year CGA . Data will be reviewed to determine if 
diagnoses are made in a timely fashion and if the diagnoses are reported accurately.  
 
9.4.5  BASELINE DESCRIPTIVE  STATISTICS  
 
Population description: Gestational age, birth weight, day of life at admission , and 
length of stay in the hospital  will be summarized with means, medians, standard 
deviations, inter -quartile ranges, and 95% confidence intervals (CI). Prenatal 
evaluations, complications , and mode of delivery  will be summarized with frequencies 
and perc entages.  Signs/  symptoms that warranted the testing will be summarized with 
frequencies and percentages.   
 
9.4.6  PLANNED INTERIM ANAL YSES  
 
Interim analyses are  not planned.  
 
9.4.7  SUB -GROUP ANALYSES  
 
The primary or secondary endpoints will not be analyzed by demographic sub -groups; 
we do not expect different results according to sex or race/ethnicity.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
78  
9.4.8  TABULATION OF INDIVI DUAL PARTICIPANT DATA  
 
N/A 
 
9.4.9  EXPLORATORY ANALYSES  
 
A review of the conditions det ected by rWGS  but not NewbornDx  will be conducted and 
this review may potentially improve the NewbornDx  panel.  
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
79 10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
 
10.1  REGULATORY, ETHICA L, AND STUDY OVERSIGHT 
CONSIDERATIONS  
 
10.1.1  INFORMED CONSENT PRO CESS  
 
10.1.1.1  CONSENT/ASSENT AND O THER INFORMATIONAL D OCUMENTS 
PROVIDED TO PARTICIP ANTS  
  
Consent materials for this protocol  include  and the Informed Consent Form  and a 
Secondary Findings Parent Handout, both of which will be IRB -approved prior to use. 
The ICF will describe in detail study procedures and risks and will include check boxes 
to elect to receive secondary findings for the infant and each biological parent. The 
same informed consent  forms  and when applicable, assent forms , will be used at all 
sites. The I CF will be translated into Spanish. Short -forms will be used for all languages 
other than English or Spanish.  
 
10.1.1.2  CONSENT PROCEDURES A ND DOCUMENTATION  
  
Documentation of Consent  
Written documentation of informed consent is required prior to enrolling in the study or 
conduct of any study procedures with the exception of IRB -approved recruitment efforts  
and the unusual circumstance described in #7 of the telephone consent procedures.  
Written documentation of consent is required for the participation by the infa nt and each 
biological parent providing a blood sample.   
 
Consent when the Parent/Guardian of the Infant or a Biological Parent is  > 18 Years  
Participation of the infant requires written documentation of consent by one parent/  
guardian.  Participation of a  biological parent requires written documentation of consent 
by that biological parent.  
 
Consent when the Parent/Guardian of the Infant is < 18 Years Old  
State  Who provides consent for the 
Infant’s participation?  Must a minor parent provide 
assent for the infant’s 
participation?  
California  Minor parent  N/A 
Massachusetts  Minor parent  N/A 
New York  Minor parent  N/A 
North Carolina  One guardian of the minor parent  No 
Ohio  Minor parent  N/A 
Pennsylvania  Minor parent  N/A 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
80 Consent when a Biological Parent is <  18 Years Old  
State  Who provides consent for 
participation by the minor 
parent?  Must a minor parent provide 
assent for his or her own 
participation?  
California  One guardian of the minor 
parent  Yes  
Massachusetts  Minor parent  N/A 
New York  Minor parent  N/A 
North Carolina  One guardian of the minor 
parent  Yes, assent signature line on 
ICF 
Ohio  One guardian of the minor 
parent  Yes, assent signature line on 
ICF 
Pennsylvania  One guardian of the minor 
parent  Yes, assent signature line on 
ICF 
 
Assent for a minor parent’s participation is required by 4 sites. North Carolina Children’s 
Hospital , Children’s Hospital of Pittsburgh and Cincinnati Children’s Hospital Medical 
Center will use an additional assent signature line on the ICF. A separate as sent form 
for participation by a minor parent will only be used by Rady Children's Hospital - San 
Diego and submitted to the central IRB at the time of their site IRB application.  
 
By signing the informed consent form, the infant’s parent/guardian agrees that the infant 
will complete all evaluations required by the study, unless the  infant’s  parent/guardian 
withdraws the infant voluntarily or the infant is withdrawn from the trial for any reason.   
 
 The original signed ICF and if applicable, assent documents, will be put in the infant’s 
research file. A copy of the signed informed consent/assent documents will be:  
• provided to the parent/guardian(s) and biological parent(s) as applicable  
• put into the infant’s medical record a nd if applicable, each parent’s medical 
record  
An entry into the infant’s medical record will indicate informed consent was obtained 
(refer to the Documentation of Informed Consent template).  
 
Process of Informed Consent  
 
Informed consent is a process ini tiated prior to the individual’s agreeing to participate in 
the study and continuing throughout the individual’s study participation.  
 
1. Research staff at the enrolling site will communicate with the clinical team prior to 
approaching a parent/guardian.  The clinical genetics team will be consulted as 
dictated by SOC  at each site . The clinicians may be asked to speak with the 
parent/guardian(s) prior to their approach by the research team depending on 
family and clinical circumstances.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
81 2. The parent/guardian(s) of the infant and as applicable, the biological parents of 
the infant, will be approached directly for consent. If the parent/guardian(s) are 
not directly available, they may be contacted via telephone in extenuating 
circumstances (s ee telephone consent below).  
3. Research staff will provide a comprehensive summary of the study including 
contact information for the research team, and if requested, consent/assent 
documents.  
4. The site -PI, co -investigator or a study coordinator who is expe rienced in genetic 
studies will obtain consent. This person will verbally explain the research study 
and answer any questions. The information available on each genetic 
sequencing platform including primary findings, secondary findings and the risk 
of finding out about mistaken paternity or suspected incest will be described 
(refer to section 2.3 Risks/Benefits). The fo llowing will be emphasized: 
participation is voluntary; the infant may be withdrawn from the study at any time 
without prejudice , and the decision not to participate will in no way adversely 
affect the quality of their infant’s medical care.   
5. The parent/g uardian(s) and biological parents will have the opportunity to review 
the written consent form and ask questions prior to signing.  Parent/guardian(s) 
will be given as much time to consider the study and read the consent 
documents as necessary.  
 
Non-English  Speakers  
1. For non -English speaking families, a fully translated standard consent or an oral 
presentation accompanied by a short form may be used to obtain informed 
consent. The fully translated consent and the short form will be approved by the 
central IRB  prior to its use.  
2. A Spanish translation of the informed consent form will be available; a short form 
will be used for all other languages. If a short form is not available for the family’s 
preferred language, consent will be obtained through a certified interpreter and 
documented on the English consent form. Short forms approved by the Johns 
Hopkins IRB can be found here: 
https://www.hopkinsmedicine.org/institutional_review_board/forms/short_form_tr
anslation.html  
3. An interpreter from the hospital will be c alled to assist with the consent process if 
needed. When an interpreter is not available in -person, a professional phone 
interpreter service may be used. Family members should not serve as an 
interpreter due to the complex nature of genetic testing.  
4. Interpreters may also serve as a witness to the short form consent process; their 
signature as an interpreter (or an interpreter reference ID number from a 
professional telephone interpreter service) will serve as a witness signature. The 
non-English speaking p articipant signs the short form consent in their language. 
The person obtaining consent  signs the English version full consent. The 
interpreter/ witness understands both languages, so signs both.  
5. The parent/guardian(s) and biological parent(s) who sign the consent documents 
will be given a copy of these documents.  
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
82 Telephone consent  
It is the intention of the study team to obtain written consent from the parent/ guardian 
for the infant and each biological parent if providing a sample whenever possible. It is 
anticipated that in certain circumstances, it may be necessary for  the consent process 
to be conducted via telephone  with written documentation of consent to follow . 
Examples of when this might be needed include: when the biologica l mother remains at 
the birthing hospital after her infant is transferred to the enrolling site and a 
parent /guardian or biological parent  cannot physically visit because the family lives too 
far away. If the consent  process is not able to be conducted  in-person, telephone 
consent may be used  with written documentation of consent to follow . 
   
The PI will ensure the procedures for securing telephone consent are followed:  
1. The absent party will be contacted by phone. The research staff will explain the 
entire research study and the process required for consent by telephone.   
An email address  or fax number will be obtained in order to forward  the consent 
document(s). A time will be scheduled for a full informed consent when both parties 
will be able to have the consent physically in front of them to sign.   For non -English 
speaking persons, refer to procedures for Non -English speaking persons above.  
2. The consent  document(s)  will be sent to the absent party. The absent party will be 
advised that they are welcome to read this document, but they will be asked not to 
sign the document until the time of the scheduled consent.  
3. At the time of the scheduled consent, the research sta ff will have a witness present 
to confirm that the telephone consent  was conducted . All study information will be 
discussed,  and any questions answered.  
4. Following the explanation of the study, the absent party will be asked to sign and 
date the document. The research staff and witness will also sign and date their copy.  
5. The absent party will be asked to return the signed document to the research team, 
either electronically or if necessary, by mail.  
6. Copies of both signed documents will be made and returned  to the absent party.  
7. Written documentation of consent will be obtained prior to any study activities with 
one exception. In the circumstance where testing is urgent (clinical situation is life -
threatening) and written documentation of consent is not readi ly feasible (i.e. no 
access to a fax machine or scanner), verbal consent as documented by the research 
staff will be sufficient to obtain, ship and process blood samples. However, written 
documentation of consent by the parent/guardian must be documented p rior to the 
return of any results.   
8. If necessary, the research staff will attempt to arrange for a blood collection kit to be 
delivered to the absent party.  In the case where the biological mother is at another 
hospital and wishes to provide a blood sample , we will work with the birthing hospital 
to collect the sample and return the consent documentation.  
9. The consent will be documented per hospital and IRB policies.  
 
New Information  
Any new information that may affect willingness to continue in the study will be 
communicated by the investigator to the parent/guardian(s) or biological parent(s) in 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
83 accordance with IRB requirements. The informed consent document will be updated 
and re -consent will be obtained if necessary.    
 
Waiver of Consent  
Waiver of consent is requested for the clinician survey . After the genomic sequencing 
result is returned for a n infant , the physician of record  for the infant  will complete a 
survey about changes in care from study results and perceived utility of testing.  
10.1.2  STUDY DISCONTINUATIO N AND CLOSURE  
 
This study may be temporarily suspended or prematurely terminated if there is 
reasonable cause. The trial will be stopped for a safety review by t he DSMB if at any 
point the act of conducting the trial is deemed detrimental or unsafe to infants . Reasons 
for stopping the trial may include the reporting of inaccurate test results due to either 
problems with the technology or the medical information interface. The trial may also be 
stopped if a data breech has occurred that puts a n infant ’s personal genomic data at 
risk. Formal stopping rules will be developed with the DSMB prior to the trial beginning.  
 
If the study is prematurely  terminated or suspended, w ritten notification  documenting 
the reason for study suspension or termination  will be provided by the study -wide 
Principal Investigator (PI) to  site investigator s, NCATS, the DSMB and the IRB. The site 
investigators  will promptly inform the parent/guardian(s) of  enrolled  infants  who have not 
yet completed the study  and inform them  of any changes to study procedures.  
  
Circumstances that may warrant termination or suspension include, but are not limited 
to: 
 Determinat ion of unexpected, significant, or unacceptable risk to infant s 
 Insufficient compliance to protocol requirements  
 Data that are not sufficiently complete and/or evaluable  
 
The s tudy may resume once concerns about safety, protocol compliance, and data 
quality are addressed , and satisfy the DSMB, NCAT S and the IRB. 
 
10.1.3  CONFIDENTIALITY AND PRIVACY  
 
Confidentiality will be maintained by the participating investigators, their staff, and the 
sponsor(s). This confidentiality covers the clinical information rela ting to participating 
infants, testing of biological samples and genetic tests .  
 
All study related material will be stored securely  by the site . Each enrolled infant will be 
assigned a unique study identification number which does not include any identifiers. 
The information entered into the password -protected REDCap  System and the 
documents used for remote monitoring will be identified by the Infant Study ID number. 
Each site will keep the link between the Infant Study ID number and infant identifiers for 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
84 all subjects enrolled at their site in a secure manner ( password -protected spreadsheet  
or hand -written log  securely locked ).  
 
The ICF will cle arly indicate that the labeling of specimens, medical information and 
reports to/from the laboratories will contain identifying information. Confirmed genomic 
testing results will be returned from the laboratory to the  site and  the infant ’s EMR and 
will co ntain patient identifiers. All genomic sequencing data will be electronically stored 
in password -protected databases at the laboratory that conducted the test.  
 
Paper -based study files, including the original ICF /assent documents  and contact 
information  related to the infant will be stored in a secure  office of the research staff for 
internal use during the study . A copy of the signed ICF will be placed in the infant ’s 
medical record . At the end of the study, all records will continue to be kept in a secure  
location  (i.e. a secure storage facility)  for as long a period as dictated by the reviewing 
IRB, Institutional policies, or sponsor requirements.  
 
Study research data  about the infant , which is for purposes of statistical analysis and 
scientific reporting , will be transmitted to and stored at the Tufts Medical Center  Data 
Coordinating Center. The REDCap  and study management systems used by clinical 
sites and by Tufts Medical Center research staff will be secured and password 
protected. At the end of the st udy, all study databases will be de -identified and archived 
at Tufts Medical Center.  
 
Per Section 2012 of the 21st Century Cures Act as implemented in the 2017 NIH 
Certificates of Confidentiality Policy, this study is automatically issued a COC. This 
certificate protects identifiable research information from forced disclosure. It allows the 
investigator and others who have access to research records to refuse to disclose 
identifying information on research participation in any civil, criminal, administrati ve, 
legislative, or other proceeding, whether at the federal, state, or local level. By 
protecting researchers and institutions from being compelled to disclose information that 
would identify research participants, Certificates of Confidentiality help ach ieve the 
research objectives and promote participation in studies by helping assure 
confidentiality and privacy to participants. The fact that a COC may not apply in all 
circumstances is disclosed in the ICF.  
 
Clinical information will not be released with out written permission of the infant ’s 
parent/guardian , except as necessary for monitoring by the research staff for this study, 
IRB, DSMB,  NIH, or OHRP. Senior project leadership  or other authorized 
representatives may inspect all documents and records re quired to be maintained by 
the PIs. This documentation includes, but is not limited to medical records (office, clinic, 
or hospital) for the infant s in this study. Clinical study sites will permit access to such 
records.  
 
Protection against a data securit y breach  
 Paper -based study files, including original signed ICFs, will be stored in a locked 
office of the study team members or a secure storage facility. A copy of the 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
85 signed ICF will be placed in the subject’s medical record (paper or scanned in to 
the EMR as applicable). All genomic sequencing data will be electronically stored 
accessible only to research personnel.   
 The RCIGM ordering portal to which each infant’s medical record is uploaded is 
HIPAA -compliant and requires a login and password  
 Any PHI distributed over email (return of results) must be encrypted and 
distributed via secure institutional email systems. Results will be returned to the 
electronic medical record consistent with each site’s HIPAA -compliant 
institutional policies.  
 Electronic s tudy files containing PHI (i.e. a screening log) at each site must be 
kept secure (i.e. password -protected file in a restricted access folder maintained 
on a secure internal institutional server)  
 The REDCap  system is password protected; limited staff at each site will be 
granted password login ID. All personnel must provide an active organizational 
email address before being issued an ID. The REDCap  system requires complex 
passwords, and the frequency of for ced password changes is every 90 days. 
Enrolling sites will only have access to data entered into the REDCap  system for 
infants enrolled at their own site with the exception of the study -wide PIs, DCC 
and monitoring personnel who will have access to all si tes’ data. Enrolling sites 
will not have access to export study data.  
 The data center in which the REDCap  servers are housed has strict access 
control; only authorized core personnel may access the facility unescorted. Only 
authorized users are allowed to  connect to the network and the security of the 
network is actively monitored. Power and environmental controls have several 
layers of backups . The institution actively logs and monitors all communication to 
the server (multiple firewall layers prevent dir ect external communication to the 
server) and is alerted to any unusual activity. If warranted, the institution will 
immediately as well as automatically ban offending IP addresses at the perimeter 
before they reach the server. The application itself also rejects and bans IP 
addresses of anything it considers abnormal access. REDCap  Server(s) are 
regularly backed up. All transactions are securely delivered to the application 
using SSL (SHA ‐1 with RSA Encryption; 2048 ‐bits). It is then transmitted 
internally  (behind the firewall) to the database server. All transactions are logged 
at the server layer (http logging), application layer ( REDCap  logs activity to a 
database table), and the database layer.  
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
86 10.1.4  FUTURE USE OF STORED  SPECIMENS AND DATA  
  
Blood samples/DNA  
Blood  samples /DNA will be kept by the laboratories for the duration of the study period 
(up to 5 years) for the purpose of further testing of the infant.  The specimens will then 
be destroyed at the conclusion of the study .   
 
Raw Sequencing Data   
The raw sequencing data generated by this research will be kept by Athena (Quest)  
Diagnostics and RCIGM for at least the length of the 5-year study period. The 
laboratories may destroy raw sequencing data after the conclusion of the study  but 
should not do so without permission from the study wide PIs. Prior to destruction of any 
raw sequencing data, g enomic sequencing data may be : 
1. Used to re -analyze VUS; in the event an infant’s diagnosis changes, we will 
attempt to contact the parents  
2. De-identified  and transferred to a third party  for use in a future study to further 
understand neonatal and childhood diseases  
 
Sharing of Genomic Research Data  
This prospective, multi -center clinical trial will generate genomic sequencing data that is 
classified as ‘Level 4’Data by the Genomic Data Sharing (GDS) Policy of the National 
Institutes of Health. Sequencing data that relates genomic data to phenotype or other 
biological states will be generated. As such, all human genomic data will be released in  
accordance to the NIH GDS Policy which establishes the timelines for submission and 
subsequent release of data for access by secondary investigators. Specifically , data  
(results of testing) will be provided to infant s and their caregivers when complete and 
validated  (with the exception of provisional results which are given prior to confirmation) . 
In addition, data, including genome sequences (fastq files), variants (vcf files), and 
associated HIPAA compliant clinical metadata will be deposited in the Lo ngitudinal 
Pediatric Data Resource (LPDR; https://www.nbstrn.org/research -tools/longitudinal -
pediatric -data-resource). The LPDR is being developed by the Newborn Screening 
Translational Research Network (NBSTRN). The LPDR is a secure informatics system 
designed to enable enhanced data collection, sharing, management and analysis for 
conditions identified as part of newborn screening or for conditions that may benefit 
from newborn screening, including NICU genomic sequencing. The NBSTRN is funded 
by the NICH D (contract #HHSN275201300011C). The LPDR is currently being used to 
deposit data from infant s in the NICU and PICU who have already had rWGS  performed 
related to the NICHD/NHGRINSIGHT program  (PI Dr. Kingsmore). M uch of the 
infrastructure for those datase ts will serve as a template for the dissemination of data 
from this proposal. The LPDR, in turn, will deposit data in the Controlled Access section  
of the NCBI dbGAP. Variants with ACMG recommended pathogenicity assessments will 
be deposited in  ClinVar. No vel disorder  gene assertions will be deposited in ClinGen 
(https://clinicalgenome.org/ ). We anticipate annual data submissions supplemented  by 
specific dataset deposits as manuscripts arising from  this work are submitted for 
publication.  
 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
87 10.1.5  KEY ROLES AND STUDY GOVERNANCE   
  
Co-Principal Investigators:  
 
Jonathan M. Davis, MD  
Tufts Medical Center  
800 Washington Street, Box 44, Boston, MA 02111  
Tel: 617 -636-5322  
jdavis@tuftsmedicalcenter.org  
 
Jill Maron, MD, MPH  
Tufts Medical Center  
800 Washington Street, Box 44, Boston, MA 02111  
Pager: 617 -647-2971  
jmaron@tuftsmedicalcenter.org  
 
10.1.6  SAFETY OVERSIGHT  
 
DSMB  
Safety oversight will be under the direction of a Data and Safety Monitoring Board 
(DSMB). The DSMB is composed of individuals with the appropriate expertise, including 
an ethicist, geneticist, neonatologist and statistician :  
 
Tamsin Knox, MD, MPH (CHAIR)  
Associ ate Director, Regulatory Group, Tufts Clinical and Translational Science Institute  
Tufts University School of Medicine  
150 Harrison Avenue, Jaharis 2, Boston, MA 02111  
Tel: 617.636.3558  
tamsin.knox@tufts.edu  
 
Jonathan M. Fanaroff MD, JD  
Professor of Pedia trics 
Case Western Reserve University School of Medicine  
Director, Rainbow Center for Pediatric Ethics  
Co-Medical Director, Neonatal Intensive Care Unit  
Rainbow Babies & Children's Hospital  
Cleveland, Oh 44106  
 
Gina M. Geis, MD, MS  
Attending Neonatologist  
Associate Director, Neonatal -Perinatal Medicine Fellowship Program  
Associate Professor of Pediatrics  
Associate Professor in the Center for Bioethics, Education and Research  
Albany Medical Center  
Department of Pediatrics, Division of Neonatology  
Albany, NY 12208     
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
88  
Stephanie Sacharow, MD, FACMG  
Assistant Professor, Harvard Medical School  
Medical Genetics, Medical Biochemical Genetics  
Boston Children’s Hospital  
Division of Genetics and Genomics  
 
Hong Chang, PhD  
Statistician and Senior Project Manager, Biost atistics, Epidemiology, and Research 
Design (BERD) Center  
Assistant Professor  
Tufts University School of Medicine  
Boston, MA  
 
Members of the DSMB are independent from the study conduct and free of conflict of 
interest. The DSMB will meet at least annually to assess safety data or more often if 
needed. The DMSB will operate under the rules of an approved charter that will be 
written and reviewed at the organizational meeting of the DSMB. At this time, each data 
element the DSMB needs to assess will be clearl y defined. The DSMB will provide its 
input to NCATS.  
 
Steering Committee  
The Steering Committee (Drs. Davis, Diacovo, Gelb, Ginns, Kingsmore, Maron, 
Poindexter, Powell and Vockley ) with significant expertise in neonatal clinical trials and 
genomic medicine/testing will oversee the conduct of the trial. The Steering Committee 
will have conference calls every three months (or more often if needed) to review any 
problems, issues, and o perations for the study.  
 
10.1.7  CLINICAL MONITORING  
Clinical site monitoring will be conducted remotely by Tufts Medical Center research 
staff to ensure that 1) the rights and well -being of trial participants are protected; 2) the 
reported trial data are accurate, complete, and verifiable; and 3) the conduct of the trial 
is in compliance with the currently approved protocol/  amendment(s)  and with 
applicable requirement(s) as outlined in the DSMP.   
 Data monitoring will be conducted remotely (enrolling sites  will upload de -identified 
medical records and source documents to the REDCap  system for reference by 
monitoring personnel)  
 Data monitoring will consist of examination of data and processes related to 
informed consent, subject eligibility, the accuracy of study primary endpoints, and 
safety/adverse events as outlined in the DSMP  
 Although monitoring will occur throughout the study, the frequency of monitoring will 
vary for each specific process or data point as outlined in the DSMP   
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
89  The study -wide Co -PIs wi ll be provided copies of monitoring reports quarterly  
 Monitoring will include, but are not limited to, review of essential documents, 
accountability records, CRFs, ICFs, medical and laboratory reports, and protocol 
compliance  
 Each site principal investigat or will provide direct access to study -related documents 
for monitoring and auditing by the data coordinating center or its representative, and 
inspection by local and regulatory authorities  
 If a significant number of issues at a site are identified, addit ional training, increased 
remote monitoring or in -person monitoring may occur  
10.1.8  QUALITY ASSURANCE AN D QUALITY CONTROL  
 
The site PI will provide direct access to all trial -related sites, source data/documents, 
case report forms, and reports for the purpose of monitoring and auditing by Tufts 
Medical Center , and inspection by local and regulatory authorities. The site PI will also 
ensur e that all study personnel are appropriately trained  and the applicable 
documentation is maintained on site.  
 
Tufts Medical Center  research staff will verify that the clinical trial is conducted,  and the 
data generated, documented (recorded), and reported in compliance with the protocol  
and 45 CFR Part 46  as outlined in the DSMP.  
 
The DCC will implement quality control procedures beginning with the data entry system 
and generate data quality control checks , such as automatic range checks, to identify 
data that appear inconsistent, incomplete, or inaccurate . Any missing data or data 
anomalies will be communicated to the site(s) for prompt clarification and resolution.    
 
10.1.9  DATA HANDLING AND RE CORD KEEPING  
 
10.1.9.1  DATA COLLECTION AND  MANAGEMENT RESPONSIB ILITIES  
 
Data collection is the responsibility of site staff under the supervision of the site PI. The 
investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported. Adverse events must be graded, assessed for severity 
and causality, and reviewed by the site principal investigator or designee.  
The DCC for this study will be responsible for data management, quality review, 
analysis, and reporting of the study data.  
 
Data for each participant will be captured on eCRFs . Study personnel at each site will 
enter clinical data from the medical record or source document directly into REDCap . 
The data system includes password protection and internal quality checks, such as 
automatic range checks, tracking of missing data , and the ability to create and track 
manual queries. The medical record will serve as the source documents in most cases . 
However, some data may need to be captured separately on a source document (for 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
90 example, date and time of sample collection). All sou rce documents should be 
completed to ensure accurate interpretation of data. When making a change or 
correction, the original entry should be crossed out with a single line, and the change 
should be initialed and dated. Avoid the use of erasers, overwritin g, or correction 
fluid/tape on the original. Data reported in the eCRF should be consistent with the 
source  documents  or the discrepancies should be documented in a note -to-file.   
 
10.1.9.2  STUDY RECORDS RETENT ION  
 
Records and documents pertaining to the conduct of this study, including source 
documents, consent forms, and laboratory results must be retained by the investigator 
for at least 7 years after the end of the study  or longer as applicable to  
local/state/federal regulation s. No records will be destroyed w ithout the written consent 
of NIH. It is the responsibility of the overall study PIs to inform the site investigators 
when these documents no longer need to be retained.  
 
10.1.10  PROTOCOL DEVIATIONS  
 
A protocol deviation is any non -compliance with the clinical trial protocol  or manual of 
procedures requirements. The non -compliance may be on the part of the participant, the 
investigator, or the study site staff. It is the responsibility of the site to identify protocol 
deviations and to promptly develop and implement corrective  actions. All deviations 
from the protocol must be reported in REDCap  under the protocol deviation eCRF within 
5 working days of identification. A completed and investigator -signed copy of the 
protocol deviation form must be maintained in the file of essen tial documents. Protocol 
deviations must be submitted to the IRB per their guidelines. The site PI/study staff is 
responsible for knowing and adhering to the central IRB requirements.   
 
10.1.11  PUBLICATION AND DATA  SHARING POLICY  
 
This study will  be conducted in accordance with the following  publication and data 
sharing  policies and regulations:  
 The National Institutes of Health ( NIH) Public Access Policy, which ensures that 
the public has access to the published results of NIH funded research , requires 
scientists  to submit final peer -reviewed journal manuscripts that arise from NIH 
funds to the digital archive PubMed Central  upon acceptance for publication.  The 
policy stipulates that these papers must be accessible to the public on PubMed 
Central no later than 12 months after publication.   
 This study will comply with the NIH Data Sharing Policy and Policy on the 
Dissemination of NIH -Funded Clinical Trial In formation and the Clinical Trials 
Registration and Results Information Submission r ule. As such,  this trial will be  
registered at ClinicalTrials.gov, and results information from this  trial will be 
submitted to ClinicalTrials.gov.  In addition, every attemp t will be made to publish 
results in peer -reviewed journals.  Data from this study may be request ed from 
other researchers after the completion of the primary endpoint by contacting the 
Co-PIs Jonathan Davis or Jill Maron .  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
91  This study will also comply with the NIH Genomic Data Sharing Policy , which  
applies to all NIH -funded research that generates large -scale human or non -
human genomic data, as well as the use of these data for subsequent research. 
Large -scale data include genome -wide association  studies (GWAS), single 
nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, 
epigenomic, and gene expression data . Refer to section 10.1.4 of this protocol 
for further information.  
 
In addition, the following groups may share the data to improve new treatments or other 
clinical trials  (this language will be included in the ICF) : 
 Health authorities throughout the world (e.g., Food and Drug Administration, 
European Medicines Agency, NIH , etc.) 
 Institutional Review Boards  
 Other groups  such as academic, government, or industry researchers; public -
private partnerships; and/or external research collaborations. These entities will 
have oversight committees that will supervise the ethical use of the data  
 
The Steering  Committee will be responsible for developing publication procedures and 
resolving authorship issues.     
 
If the parent/guardian would like to enroll the infant or him or herself in another research 
study that will utilize sequencing data, the enrolling s ite/labs may give the raw 
sequencing data from th e GEMINI  study directly to the other study upon receipt of a 
HIPAA authorization form signed by the infant’s parent/guardian.  
 
10.1.12  CONFLICT OF INTEREST  POLICY  
 
The independence of this study from any actual or perceived influence is  critical.  
Therefore , any conflict of interest of persons who have a role in the design, conduct, 
analysis, publication, or any aspect of this trial will be disclosed. Furthermore, pe rsons 
who have a perceived conflict of interest will be required to have such conflicts 
managed in a way that is appropriate to their participation in the design and conduct of 
this t rial. Site investigators/study team members must adhere to their local re quirements 
for disclosure of conflicts of interest  and the local site reviews and manages any 
reported conflicts of interests . The local site  must provide a copy of each research team 
members’ reported conflict of interests to 1) the JHU IRB and 2) the stu dy-wide co -PIs. 
The JHU IRB will receive any management plans from relying sites and review  them as 
part of oversight/review responsibilities but does not  perform the initial review instead  of 
the local site nor manage  reported interests . 
 
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
92 11 ABBREVIATIONS  
 
ACMG  American College of Medical Genetics  and Genomics  
AE Adverse Event  
ASHG  American Society of Human Genetics  
BW Birth Weight  
BWA  Burrows -Wheeler Aligner  
CFR Code of Federal Regulations  
CGA   Corrected Gestational Age  
CLIA  Clinical Laboratory Improvement Amendments  
CNVs  Copy Number Variants  
COC  Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
CRF Case Report Form  
DBS Dried Blood Spot  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DRE  Disease -Related Event  
DRG   Diagnosis -Related Group  
DSMB  Data Safety Monitoring Board  
DSMP  Data Safety and Monitoring Plan  
EC Ethics Committee  
eCRF  Electronic Case Report Forms  
EMA  European Medicines Agency  
EMR  Electronic Medical Record  
FDA Food and Drug Administration  
GA Gestational Age  
GATK   Genome Analysis Toolkit  
GCP  Good Clinical Practice  
GDS   Genomic Data Sharing  
GINA  Genetic Information Nondiscrimination Act  
GLP Good Laboratory Practices  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
93 GWAS  Genome -Wide Association Studies  
HIPAA  Health Insurance Portability and Accountability Act  
HPO  Human Phenotype Ontology  
ICF Informed Consent Form  
ICH International Conference on Harmonisation   
ICMJE  International Committee of Medical Journal Editors  
IGV  Integrated Genome Viewer  
INC  International Neonatal Consortium  
IRB Institutional  Review Board  
LAR Legally Authorized Representative  
MOP  Manual of Procedures  
N  Number (typically refers to participants)  
NBS  Newborn Screening  
NCATS   National Center for Advancing Translational Sciences  
NICU  Neonatal Intensive Care Unit  
NIH  National Institutes of Health  
NPV  Negative Predictive Value  
OHRP  Office for Human Research Protections  
OMIM   Online Mendelian Inheritance in Man  
PCR   Polymerase Chain Reaction  
PHI  Protected Health Information  
PI Principal Investigator  
PMA  Postmenstrual age (gestational age plus postnatal age)  
PNA Postnatal age  
PPV  Positive  Predictive Value  
QA Quality Assurance  
QALY   Quality -Adjusted -Life Year  
QC Quality Control  
RCIGM   Rady Children’s Institute for Genomic Medicine  
rWES  Rapid Whole Exome Sequencing  
rWGS  Rapid Whole Genome Sequencing  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
94 SAE Serious Adverse Event  
SAP Statistical Analysis Plan  
SNP Single nucleotide polymorphism  
SOA  Schedule of Activities  
SOC  Standard of Care  
SOC  System Organ Class  
SOP  Standard Operating Procedure  
STR  Short Tandem Repeat  
Sub-I  Sub Investigator  
SVs  Structural Variants  
NewbornDx   NewbornDx Sequencing Evaluation  
UP Unanticipated Problem  
US United States  
WES  Whole Exome Sequencing  
WGS  Whole Genome Sequencing  
 
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
95 12 PROTOCOL AMENDMENT H ISTORY  
 
The table below is intended to capture changes of IRB -approved versions of the 
protocol, including a descript ion of the change and rationale .  
 
Version & Date  Description of Change  Brief Rationale  
2.0, 05DEC 2019  The term incidental has been 
added to sections that refer to 
secondary findings.  The RCIGM laboratory report 
will use the term incidental 
findings, instead of secondary 
findings, to reflect that the lab 
does not conduct a targeted  
search of variants not related to 
the infant’s phenotype.   
2.0, 05DEC 2019  When samples for the infant 
and parent(s) are received at 
the same time , RCIGM will 
routinely generate infant and 
parent sequences 
simultaneously and the data all 
analyzed together as a duo/trio 
as applicable . To increase diagnostic yield 
and/or decrease the time to 
result for the subject ; 
NewbornDx is run as a trio  
when parent samples are 
available .  
2.0, 05DEC 2019  A retrospective analysis of 
infant -only data among infants 
who were initially analyzed as a 
duo or trio  will be conducted.  To provide data about how 
often a trio is needed to obtain 
the infant’s result.  
2.0, 05DEC 2019  The laboratory testing 
processes for subjects from 
Mount Sinai has been revised 
to reflect the new status of 
NewbornDx as conditionally 
approved by New York State 
and the ramifications of this 
approval on existing processes . To match  the already IRB 
approved processes included in 
the Mount Sinai Local Context 
Questionnaire as a result of  the 
conditional approval of 
NewbornDx by New York State.  
2.0, 05DEC 2019  The adjudication of discordant 
results procedures  has been 
revised and includes  the view 
by the 1) clinician directly caring 
for the subject and 2) a subset 
of the steering committe e of the 
result that aligns best with the 
infant when discordance is due 
to variant classification.  To better structure the process 
and to obtain the view of the 
clinician caring for the infant 
and an impartial sub -committee.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
96 2.0, 05DEC 2019  The exclusion  criteria “Infants 
who are not expected to receive 
medical care in the US 
healthcare system from time of 
discharge home until 1 year 
CGA” has been added.  To ensure comparable follow -up 
economic data can be used in 
the health economic analysis.   
2.0, 05DEC 2019  Text to clarify that enrollment in 
this study is not intended to 
replace targeted available 
genetic testing for obvious  
suspected disorders  have been 
added.  To clarify that enrollment should 
not be prohibited nor delayed 
for return of clinical genetic  test 
results unless the suspected 
disorder is of an obvious nature 
and therefore rWGS is not 
needed.  
2.0, 05DEC 2019  Terminology within the primary 
endpoints definitions  has been 
updated . To use consistent terminology 
across endpoints and 
definitions.  
2.0, 05DEC 2019  The option to obtain  1ml of 
blood in an EDTA tube in lieu of 
the blood spot card wh en the  3-
hour drying time for the blood 
spot card  pushes the shipment 
of samples to the next day and 
the case is urgent.  To allow flexibility in sample 
collection vehicle in urgent 
cases when waiting for the 
drying time of a dried blood spot 
card would adversely affect time 
to potential life -saving 
treatment . 
2.0, 05DEC 2019  Details about the following  have 
been deleted and moved to the 
MOP and/or eCRF instruc tions: 
Identification number 
definitions; description of eCRF; 
blood sample collection 
procedures; Athena specimen 
ID creation example; RCIGM 
portal instructions; shipping 
instructions and shipping 
addresses; contact information; 
source document types.  To streamline repetitive 
information that is more 
appropriate for the MOP . 
2.0, 05DEC 2019  A licensed genetic counselor 
may return results without an 
attending physician present if 
clinical practice is for the 
licensed genetic counselors to 
do so outside of t his study.  To align with the existing clinical 
workflow at a site in a state for 
whom genetic counseling 
licensing allows for return of 
results.  
2.0, 05DEC 2019  Procedures for when, how and 
by whom results are returned To ensure consistent 
procedures  across sites.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
97 after an infant is discharged 
home  have been added . 
2.0, 05DEC 2019  The site should wait until results 
from both NewbornDx and 
rWGS are returned before 
speaking with the 
parent/guardian about the 
results if waiting would not harm 
the infant (i .e. the result is not 
provisional or the infant does 
not require urgent testing).  To clarify  the intended timing of 
communication with the infant’s 
parent/guardian(s).  
 
2.0, 05DEC 2019  The timeframe in which to 
collect the Clinical Utility Survey  
has been expanded to include 
at discharge home or for infants 
who discharge home prior to 
the return of results , within one 
month after the return of results . To accommodate varying 
scenarios of when results are 
returned /acted upon . 
2.0, 05DEC 2019  In cases in which the infant is 
discharged home prior to the 
return of results, the Clinical 
Utility Survey should be 
completed by the clinical 
geneticist, most relevant 
subspecialist or by the site PI 
after speaking with the 
pediatrician.  To account for different 
physicians who  will follow the 
subject and act upon results as 
an outpatient.   
2.0, 05DEC 2019  Physician CPT codes  have 
been added  to the types of data 
captured.  To better describe the types of 
billing data collected.  
2.0, 05DEC 2019  A parent may only opt -in to 
receive secondary findings if 
the parent/guardian opted -in for 
infant secondary findings. 
Inclusion of a table detailing the 
results returned for the infant 
and parent based on opt -in 
status, disorder onset, if the 
result is included on the 
ACMG59 or m edically 
actionable.  To clarify  under what 
circumstances a parent may 
opt-in for additional results and 
the possible results returned for 
the infant and parent.  
2.0, 05DEC 2019  Removed clinical geneticist as a 
required input to eligibility 
discussion. The  study team will 
discuss eligibility of the infant Depending on the site and 
condition, genetics is not always 
consulted per SOC.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
98 with the attending physician of 
record and if in agreement, the 
family will be approached for 
the study.  
2.0, 05DEC 2019  The screening data captured in 
REDCap has been changed to 
replace maternal education and 
income level data with 5 -digit 
zip code and primary symptoms 
with primary system 
involvement related to patient 
nomination .  The 5 -digit zip code will be used  
in the health economic analysis.  
The change from c linical 
symptoms  to primary system (s) 
involvement related to patient 
nomination  of infants  who have 
not provided consent i s to 
reduce the risk of identification 
given the addition of  zip code.  
2.0, 05DEC 2019  Revised consent via telephone 
procedures. If the infant’s 
clinical status is life threatening 
and in -person consent or 
written documentation of 
consent via telephone is not 
feasible, verbal consent by 
telephone as documented by 
the research staff is suffi cient to 
obtain, ship and process blood 
samples; however 
documentation of written 
consent must be obtained prior 
to return of any results.  To enable the timely conduct of 
research procedures for infants 
whose clinical status is life 
threatening , whose 
parent/guardian verbally 
consents to participate in the 
study but does not have 
immediate access to a 
fax/scanner to return the signed 
ICF, and the potential  delay in 
written consent may prevent 
life-saving treatment.  
 
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
99 13 REFERENCES  
 
1. Causey TN, Bodurtha JN, Ford N. A genetic perspective on infant mortality. 
South Med J n2010;103:440 -4. 
2. HCUP National Inpatient Sample (NIS). Healthcare Cost and Utilization Project 
(HCUP). 2012; Agency  for Healthcare Research and Quality, Rockville, MD. 
www.hcup -us.ahrq.gov/nisov erview.jsp.  
3. McCandless SE, Brunger JW, Cassidy SB. The Burden of Genetic Disease on 
Inpatient Care in a  Children’s Hospital. Am J Hum Genet 2004;74:121 –7. 
4. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y et al. Molecular findings 
among patients referred  for clinical whole -exome sequencing. JAMA 
2014;312:1870 –9. 
5. Weiner J, Sharma J, Lantos J, Kilbride H. How infants die in the neonatal 
intensive care unit: trends  from 1999 through 2008. Arch Pediatr Adolesc Med 
2011;165:630 –4. 
6. Wilkinson DJ, Fitzsimons JJ, Dar gaville PA, Campbell NT, Loughnan PM, 
McDougall PN et al. Death in  the neonatal intensive care unit: changing patterns 
of end of life care over two decades. Arch Dis Child  Fetal Neonatal Ed 
2006;91:F268 –71. 
7. Hagen CM, Hansen TW. Deaths in a neonatal intensi ve care unit: a 10 -year 
perspective. Pediatr Crit  Care Med 2004;5:463 –8. 
8. Berger TM, Hofer A. Causes and circumstances of neonatal deaths in 108 
consecutive cases over a  10-year period at the Children’s Hospital of Lucerne, 
Switzerland. Neonatology 2009;95: 157–63. 
9. Ray JG, Urquia ML, Berger H, Vermeulen MJ. Maternal and neonatal separation 
and mortality  associated with concurrent admissions to intensive care units. 
CMAJ 2012;184:E956 –62. 
10. March of Dimes. 2012 Natality and infant mortality data updated. White P lains, 
NY: March of Dimes,  2012.  
11. Yoon PW, Olney RS, Khoury MJ, Sappenfield WM, Chavez GF, Taylor D. 
Contribution of birth defects  and genetic diseases to pediatric hospitalizations. A 
population -based study. Arch Pediatr Adolesc Med  1997;151:1096 –103. 
12. O’Ma lley M, Hutcheon RG. Genetic disorders and congenital malformations in 
pediatric long -term care. J Am Med Dir Assoc 2007;8:332 –4. 
13. Pinar H. Postmortem findings in term neonates. Semin Neonatol 2004;9:289 –
302. 
14. Stevenson DA, Carey JC. Contribution of malforma tions and genetic disorders to 
mortality in a  children’s hospital. Am J Med Genet A 2004;126A:393 –7. 
15. Soneda A, Teruya H, Furuya N, Yoshihashi H, Enomoto K, Ishikawa A et al. 
Proportion of  malformations and genetic disorders among cases encountered at 
a hig h-care unit in a children’s  hospital. Eur J Pediatr 2012;171:301 –5. 
16. Petrikin JE, Willig LK, Smith LD, Kingsmore SF. Rapid whole genome 
sequencing and precision  neonatology. Semin Perinatol 2015;39:623 -31. 
17. Yoon PW, Olney RS, Khoury MJ, Sappenfield WM, Chavez GF, Taylor D. 
Contribution of birth defects  and genetic diseases to pediatric hospitalizations. A 
population -based study. Arch Pediatr Adolesc Med  1997;151:1096 –103. 
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
100 18. Shashi V, McConkie -Rosell A, Rosell B, Schoch K, Vellore K McDonald M et al. 
The ut ility of the  traditional medical genetics diagnostic evaluation in the context 
of next -generation sequencing for  undiagnosed genetic disorders. Genet Med 
2014;16:176 –82. 
19. Soden S, Saunders CJ, Willig LK, Farrow EG, Smith LD, Petrikin JE et al. 
Effectiveness  of exome and  genome sequencing guided by acuity of illness for 
diagnosis of neurodevelopmental disorders. Sci  Transl Med 2014;6:265ra168.  
20. Soden SE, Saunders CJ, Dinwiddie DL, Miller NA, Atherton AM, Alnadi NA et al. 
A systematic  approach to implementing m onogenic genomic medicine. J 
Genomes Exomes 2013;1:15 –24. 
21. ACMG Board of Directors. Points to consider in the clinical application of 
genomic sequencing. Genet  Med. 2012;14:759 -61. 
22. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B et al. 
Making a definitive  diagnosis: successful clinical application of whole exome 
sequencing in a child with intractable  inflammatory bowel disease. Genet Med 
2011;13:255 –62. 
23. Stark Z, Tan TY, Chong B, Brett, GR, Yap P, Walsh M et al. A prospective 
evaluation of  whole -exome  sequencing as a first -tier molecular test in infants 
with suspected monogenic disorders. Genet Med  2016;18:1090 -1096.  
24. Miller NA, Farrow EG, Gibson M, Willig LK, Twist G, Yoo B, et al. A 26 -hour 
system of highly sensitive  whole genome sequencin g for emergency 
management of genetic diseases. Genome Med 2015;7:100.  
25. Bodian DL, Klein E, Iyer RK, Wong WS, Kothiyal P, Stauffer D et al. Utility of 
whole -genome  sequencing for detection of newborn screening disorders in a 
population cohort of 1,696 neona tes. Genet Med 2016;18:221 -30. 
26. Saunders CJ, Miller NA, Soden SE, Dinwiddle DL, Noll A, Alnadi NA et al. Rapid 
whole -genome  sequencing for genetic disease diagnosis in neonatal intensive 
care units. Sci Transl Med  2012;4:154ra135.  
27. Stranneheim H. Rapid pulsed whole genome sequencing for comprehensive 
acute diagnostics of  inborn errors of metabolism. BMC Genomics 2014;15:1090.  
28. Priest JR. Molecular diagnosis of long QT syndrome at 10 days of life by rapid 
whole genome  sequencing. Heart Rhythm 2014;11:1707 -13. 
29. Manolio TA, Abramowicz M, Al -Mulla F, Anderson W, Balling R, Berger AC, et 
al. Global  implementation of genomic medicine: We are not alone. Sci Transl 
Med 2015;7:290ps13.  
30. Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R et 
al. Imp lementing  genomic medicine in the clinic: the future is here. Genet Med 
2013;15:258 -67. 
31. Horgan D, Jansen M, Leyens L, Lal JA, Sudbrak R, Hackenitz E, et al. An index 
of barriers for the  implementation of personalised medicine and 
pharmacogenomics in Europe . Pub Health Genom  2014;17:287 -98. 
32. Roundtable on Translating Genomic -Based Research for Health, Board on 
Health Sciences Policy,  Health and Medicine Division, National Academies of 
Sciences, Engineering, and Medicine. Applying  an Implementation Science 
Approach to Genomic Medicine: Workshop Summary. Washington (DC):  
National Academies Press (US); 2016.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
101 33. Willig LK, Petrikin JE, Smith LD, Saunders CJ, Thiffault I, Miller NA et al. Whole -
genome sequencing  for identification of Mendelian disorders in critically ill 
infants: a retrospective analysis of diagnostic and  clinical findings. Lancet Respir 
Med 2015;3:377 -87. 
34. Downing GJ, Zuckerman AE, Coon C, Lloyd -Puryear MA. Enhancing the quality 
and efficiency of  newborn screening programs through the use of health 
information technology. Semin Perinatol 2010;  34:156 –62. 
35. Kuehn BM. After 50 years, newborn screening continues to yield public health 
gains. JAMA  2013;309:1215.  
36. Couce ML, Bana A, Boveda MD, Perez -Munuzuri A, Fernandez -Lorenzo JR, 
Fraga JM. Inborn errors of  metabolism in a neonatology unit: impact and long -
term results. Pediatr Int 2011;53:13 –7. 
37. Downing GJ, Zuckerman AE, Coon C, Lloyd -Puryear MA. Enhancing the quality 
and efficiency of  newborn screening programs through the use of health 
information technology.  Semin Perinatol  2010;34:156 –62. 
38. Lantos JD, Meadow WL. Costs and end -of-life care in the NICU: lessons for the 
MICU? J Law Med  Ethics 2011;39:194 -200. 
39. Weiner J, Sharma J, Lantos J, Kilbride H. Does diagnosis influence end -of-life 
decisions in the neonatal  intensive care unit? J Perinatol 2015;35:151 -4. 
40. NICU Summary. March of Dimes; 2016.  
https://www.marchofdimes.org/peristats/pdfdocs/nicu_summary_final.pdf).  
41. Embi PJ, Jain A, Clark J, Bizjack S, Hornung R, Harris CM. Effect of a clinical 
trial alert system o n physician participation in trial recruitment. Arch Intern Med 
2005;165:2272 -7. 
42. Soden SE, Saunders CJ, Dinwiddie DL, Miller NA, Atherton AM, Alnadi NA et al. 
A systematic  approach to implementing monogenic genomic medicine. J 
Genomes Exomes 2013;1:15 –24. 
43. Bhattacharjee A, Sokolsky T, Wyman SK, Reese MG, Puffenberger E, Strauss K 
et al. Development of  DNA Confirmatory and High -Risk Diagnostic Testing for 
Newborns Using Targeted Next -Generation  DNA Sequencing. Genet 
Med;17:337 -47. 
44. Brandler WM, Antaki D, Gujra l M, Noor A, Rosanio G, Chapman TR et al. 
Frequency and Complexity of De Novo Structural Mutation in Autism. Am J Hum 
Genet 2016;98:667 -79. 
45. Botkin JR, Belmont JW, Berg JS, Berkman BE, Bombard Y, Holm IA, et al. 
Points to Consider: Ethical,  Legal, and Psych osocial Implications of Genetic 
Testing in Children and Adolescents. Am J Hum Genet  2015;97:6 -21. 
46. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. 
Recommendations for reporting  of secondary findings in clinical exome and 
genome sequencing, 2 016 update (ACMG SF v2.0): a  policy statement of the 
American College of Medical Genetics and Genomics. Genet Med 2017;19:249 - 
255. 
47. Maddalena A, Bale S, Das S, Grody W, Richards S. ACMG Laboratory Quality 
Assurance Committee.Technical standards and guideli nes: molecular genetic 
testing for ultra -rare disorders. Genet Med  2005;7:571.  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
102 48. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, et al. 
ACMG recommendations for  standards for interpretation and reporting of 
sequence variations: Revisions 2007.  Genet Med  2008;10:294 -300. 
49. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier -Foster J, et al. Standards 
and guidelines for the  interpretation of sequence variants: a joint consensus 
recommendation of the American College of  Medical Genetics and Genomics 
and the Association for Molecular Pathology. Genet Med  2015;17:405 –24. 
50. Rehm HL, Bale SJ, Bayrak -Toydemir P, Berg JS, Brown KK, Deignan JL, et al. 
ACMG clinical  laboratory standards for next -generation sequencing. Genet Med 
2013;15:733 –47. 
51. Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, et al. 
DECIPHER: Database of  Chromosomal Imbalance and Phenotype in Humans 
using Ensembl Resources. Am J Hum Genet  2009;84:524 –33. 
52. https://macarthurlab.org/2017/02/27/the -genome -aggregation -database -
gnom ad/. 
53. Köhler S, Schulz MH, Krawitz P, Bauer S, Dölken S, Ott CE et al. Clinical 
diagnostics in human  genetics with semantic similarity searches in ontologies. 
Am J Hum Genet 2009;85:457 -64. 
54. Köhler S, Vasilevsky NA, Engelstad M, Foster E, McMurry J, Ségolène  A et al., 
The Human Phenotype  Ontology in 2017. Nucleic Acids Res 2017;45:D865 -76. 
55. Noll AC, Miller NA, Smith LD, Yoo B, Fiedler S, Cooley LD et al. Clinical 
detection of deletion structural  variants in whole -genome sequences. npj 
Genomic Medicine 2016:160 26. 
56. http://www.ninds.nih.gov/funding/areas/translational_research/Early_Translation
al_Grant_List.htm.  
57. Berg JS, Agrawal PB, Bailey DB Jr, Beggs AH, Brenner SE, Brower AM et al. 
Newborn sequencing in  genomic medicine and public health. Pediatrics 
2017;epub a head of print.  
58. Stark Z, Schofield D, Alam K, Wilson W, Mupfeki N, Macciocca I, Shrestha R, 
White SM, Gaff C.  Prospective comparison of the cost -effectiveness of clinical 
whole -exome sequencing with that of usual  care overwhelmingly supports early 
use and r eimbursement. Genet Med 2017;epub ahead of print.  
59. Cost effectiveness in health and medicine. Eds: Neumann PJ, Sanders GD, 
Russell LB, Siegel JE,  Ganiats TG. Chapter 7, Valuing Health Outcomes.  
60. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M et a l. 
Recommendations for  conduct, methodological practices, and reporting of cost -
effectiveness analyses: second panel on cost effectiveness  in health and 
medicine. JAMA 2016;316:1093 -103. 
61. Prosser LA, Hammitt JK, Keren R. Measuring health preferences for use  in cost -
utility and cost -benefit analyses of interventions in children: theoretical and 
methodological considerations . Pharmacoeconomics 2007;25:713 -26.  
62. American College of Medical Genetics and Genomics, www.acmg.net.  
63. National Society of Genetic Counselo rs. 2016; 
http://www.nsgc.org/page/whoaregeneticcounselors  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
103 64. Saul RA, Trotter T, Sease K, Tarini B. Survey of family history taking and genetic 
testing in pediatric  practice. J Community Genet 2017 doi: 10.1007/s12687 -016-
0291 -3. 
65. Plon SE, Eccles DM, Easton D , Foulkes WD, Genuardi M, Greenblatt MS, et al. 
IARC Unclassified  Genetic Variants Working Group. Sequence variant 
classification and reporting: recommendations for  improving the interpretation of 
cancer susceptibility genetic test results. Hum Mutat 2008; 29:1282 -91. 
66. Ellsworth MA, Lang TR, Pickering BW, Herasevich V. Clinical data needs in the 
neonatal intensive care  unit electronic medical record. BMC Med Inform Decis 
Mak. 2014;14:92.  
67. Williams JL, Rahm AK, Stuckey H, Green J, Feldman L, Zallen DT, et al. 
Enhancing genomic laboratory  reports: A qualitative analysis of provider review. 
Am J Med Genet A. 2016;170A:1134 -41. 
68. http://ww2.amstat.org/sections/SRMS/Proceedings/y2 008/Files/flanigan.pdf . 
69. Fagerland, Morten W., Stian Lydersen, and Petter Laake. "Recommended tests 
and confidence intervals for paired binomial proportions." Statistics in medicine 
33.16 (2014): 2850 -2875.  
70. Farnaes L. et al. 2018. Rapid whole -genome sequenc ing decreases infant 
morbidity and cost of hospitalization. npg Genomic Medicine 3:10  
71. Karbassi et al Hum Mutat 37:127 –134, 2016, DOI: 10.1002/humu.22918  
 
  
Genomic Medicin e for Ill Neonates and Infants (The GEMINI Study)  Version 2.0 
  05DEC2019  
 
104 14 APPENDICES  
 
 Informed Consent Form   
 Secondary Findings Parent Handout  
 Follow -up Contact Information Form  
 Resource Utilization Follow -up Email and Questionnaire  
 SF-12 Your Health and Well Being  
 Child Visual Analog Scale instrument  
 Authorization to Release Protected Health Information  
 Clinician Assessment of Clinical Utility  
 